<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:43:03Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8048381" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8048381</identifier>
        <datestamp>2021-04-15</datestamp>
        <setSpec>phewolters</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Circ Res</journal-id>
              <journal-id journal-id-type="iso-abbrev">Circ Res</journal-id>
              <journal-id journal-id-type="publisher-id">RES</journal-id>
              <journal-title-group>
                <journal-title>Circulation Research</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0009-7330</issn>
              <issn pub-type="epub">1524-4571</issn>
              <publisher>
                <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
                <publisher-loc>Hagerstown, MD</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8048381</article-id>
              <article-id pub-id-type="pmcid">PMC8048381</article-id>
              <article-id pub-id-type="pmc-uid">8048381</article-id>
              <article-id pub-id-type="pmid">33557580</article-id>
              <article-id pub-id-type="pmid">33557580</article-id>
              <article-id pub-id-type="art-access-id">00005</article-id>
              <article-id pub-id-type="doi">10.1161/CIRCRESAHA.120.316966</article-id>
              <article-categories>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>10050</subject>
                  <subject>10052</subject>
                  <subject>10084</subject>
                  <subject>10093</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Mechanisms of Congenital Heart Disease Caused by NAA15 Haploinsufficiency</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ward</surname>
                    <given-names>Tarsha</given-names>
                  </name>
                  <email>Tarsha_Ward@hms.harvard.edu</email>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tai</surname>
                    <given-names>Warren</given-names>
                  </name>
                  <email>warrentai1@gmail.com</email>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Morton</surname>
                    <given-names>Sarah</given-names>
                  </name>
                  <email>Sarah.Morton@childrens.harvard.edu</email>
                  <xref ref-type="aff" rid="aff1">1</xref>
                  <xref ref-type="aff" rid="aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Impens</surname>
                    <given-names>Francis</given-names>
                  </name>
                  <email>francis.impens@vib-ugent.be</email>
                  <xref ref-type="aff" rid="aff4">4</xref>
                  <xref ref-type="aff" rid="aff5">5</xref>
                  <xref ref-type="aff" rid="aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Van Damme</surname>
                    <given-names>Petra</given-names>
                  </name>
                  <email>Petra.vandamme@ugent.be</email>
                  <xref ref-type="aff" rid="aff7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Van Haver</surname>
                    <given-names>Delphi</given-names>
                  </name>
                  <email>delphi.vanhaver@vib-ugent.be</email>
                  <xref ref-type="aff" rid="aff4">4</xref>
                  <xref ref-type="aff" rid="aff5">5</xref>
                  <xref ref-type="aff" rid="aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Timmerman</surname>
                    <given-names>Evy</given-names>
                  </name>
                  <email>evy.timmerman@vib-ugent.be</email>
                  <xref ref-type="aff" rid="aff4">4</xref>
                  <xref ref-type="aff" rid="aff5">5</xref>
                  <xref ref-type="aff" rid="aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Venturini</surname>
                    <given-names>Gabriela</given-names>
                  </name>
                  <email>venturini.gabriela@gmail.com</email>
                  <xref ref-type="aff" rid="aff1">1</xref>
                  <xref ref-type="aff" rid="aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zhang</surname>
                    <given-names>Kehan</given-names>
                  </name>
                  <email>kehan@bu.edu</email>
                  <xref ref-type="aff" rid="aff9">9</xref>
                  <xref ref-type="aff" rid="aff10">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jang</surname>
                    <given-names>Min Young</given-names>
                  </name>
                  <email>megan.jang@gmail.com</email>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Willcox</surname>
                    <given-names>Jon A.L.</given-names>
                  </name>
                  <email>Jon_Willcox@hms.harvard.edu</email>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Haghighi</surname>
                    <given-names>Alireza</given-names>
                  </name>
                  <email>AHAGHIGHI@BWH.HARVARD.EDU</email>
                  <xref ref-type="aff" rid="aff1">1</xref>
                  <xref ref-type="aff" rid="aff2">2</xref>
                  <xref ref-type="aff" rid="aff11">11</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gelb</surname>
                    <given-names>Bruce D.</given-names>
                  </name>
                  <email>bruce.gelb@mssm.edu</email>
                  <xref ref-type="aff" rid="aff12">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chung</surname>
                    <given-names>Wendy K.</given-names>
                  </name>
                  <email>wkc15@cumc.columbia.edu</email>
                  <xref ref-type="aff" rid="aff13">13</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Goldmuntz</surname>
                    <given-names>Elizabeth</given-names>
                  </name>
                  <email>goldmuntz@email.chop.edu</email>
                  <xref ref-type="aff" rid="aff14">14</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Porter</surname>
                    <given-names>George A.</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <email>george_porter@urmc.rochester.edu</email>
                  <xref ref-type="aff" rid="aff15">15</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lifton</surname>
                    <given-names>Richard P.</given-names>
                  </name>
                  <email>rickl@mail.rockefeller.edu</email>
                  <xref ref-type="aff" rid="aff16">16</xref>
                  <xref ref-type="aff" rid="aff17">17</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Brueckner</surname>
                    <given-names>Martina</given-names>
                  </name>
                  <email>martina.brueckner@yale.edu</email>
                  <xref ref-type="aff" rid="aff16">16</xref>
                  <xref ref-type="aff" rid="aff18">18</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yost</surname>
                    <given-names>H. Joseph</given-names>
                  </name>
                  <email>jyost@genetics.utah.edu</email>
                  <xref ref-type="aff" rid="aff19">19</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bruneau</surname>
                    <given-names>Benoit G.</given-names>
                  </name>
                  <email>bbruneau@gladstone.ucsf.edu</email>
                  <xref ref-type="aff" rid="aff20">20</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gorham</surname>
                    <given-names>Joshua</given-names>
                  </name>
                  <email>jgorham@genetics.med.harvard.edu</email>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kim</surname>
                    <given-names>Yuri</given-names>
                  </name>
                  <email>ykim@genetics.med.harvard.edu</email>
                  <xref ref-type="aff" rid="aff1">1</xref>
                  <xref ref-type="aff" rid="aff21">21</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pereira</surname>
                    <given-names>Alexandre</given-names>
                  </name>
                  <email>alexandre.pereira@incor.usp.br</email>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Homsy</surname>
                    <given-names>Jason</given-names>
                  </name>
                  <email>jason.homsy@gmail.com</email>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Benson</surname>
                    <given-names>Craig C.</given-names>
                  </name>
                  <email>craigcbenson@gmail.com</email>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>DePalma</surname>
                    <given-names>Steven R.</given-names>
                  </name>
                  <email>depalma@genetics.med.harvard.edu</email>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Varland</surname>
                    <given-names>Sylvia</given-names>
                  </name>
                  <email>Sylvia.Varland@uib.no</email>
                  <xref ref-type="aff" rid="aff22">22</xref>
                  <xref ref-type="aff" rid="aff23">23</xref>
                  <xref ref-type="aff" rid="aff24">24</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chen</surname>
                    <given-names>Christopher S.</given-names>
                  </name>
                  <email>chencs@bu.edu</email>
                  <xref ref-type="aff" rid="aff9">9</xref>
                  <xref ref-type="aff" rid="aff10">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Arnesen</surname>
                    <given-names>Thomas</given-names>
                  </name>
                  <email>Thomas.Arnesen@uib.no</email>
                  <xref ref-type="aff" rid="aff22">22</xref>
                  <xref ref-type="aff" rid="aff23">23</xref>
                  <xref ref-type="aff" rid="aff25">25</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gevaert</surname>
                    <given-names>Kris</given-names>
                  </name>
                  <email>kris.gevaert@vib-ugent.be</email>
                  <xref ref-type="aff" rid="aff6">6</xref>
                  <xref ref-type="fn" rid="fn01">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Seidman</surname>
                    <given-names>Christine</given-names>
                  </name>
                  <email>seidman@genetics.med.harvard.edu</email>
                  <xref ref-type="aff" rid="aff1">1</xref>
                  <xref ref-type="aff" rid="aff2">2</xref>
                  <xref ref-type="aff" rid="aff11">11</xref>
                  <xref ref-type="fn" rid="fn01">*</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Seidman</surname>
                    <given-names>J.G.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                  <xref ref-type="fn" rid="fn01">*</xref>
                </contrib>
                <aff id="aff1"><label>1</label>Genetics (T.W., W.T., S.M., G.V., M.Y.J., J.A.L.W., A.H., J.G., Y.K., A.P., J.H., C.C.B., S.R.D., C.S., J.G.S.), Harvard Medical School.</aff>
                <aff id="aff2"><label>2</label>Howard Hughes Medical Institute (A.H., C.S.), Harvard Medical School.</aff>
                <aff id="aff3"><label>3</label>Division of Newborn Medicine, Boston Children’s Hospital (S.M.).</aff>
                <aff id="aff4"><label>4</label>VIB Center for Medical Biotechnology, B-9000 Ghent, Belgium (F.I., D.V.H., E.T., K.G.).</aff>
                <aff id="aff5"><label>5</label>VIB Proteomics Core, B-9000 Ghent, Belgium (F.I., D.V.H., E.T.).</aff>
                <aff id="aff6"><label>6</label>Biomolecular Medicine (F.I., D.V.H., E.T., K.G.), Ghent University, B-9000 Ghent, Belgium.</aff>
                <aff id="aff7"><label>7</label>Biochemistry and Microbiology (P.V.D.), Ghent University, B-9000 Ghent, Belgium.</aff>
                <aff id="aff8"><label>8</label>University of Sao Paulo (G.V.).</aff>
                <aff id="aff9"><label>9</label>Biomedical Engineering, Boston University, MA (K.Z., C.S.C.).</aff>
                <aff id="aff10"><label>10</label>The Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA (K.Z., C.S.C.).</aff>
                <aff id="aff11"><label>11</label>Medicine, Brigham and Women’s Hospital (A.H., C.S.).</aff>
                <aff id="aff12"><label>12</label>Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York (B.D.G.).</aff>
                <aff id="aff13"><label>13</label>Pediatrics and Medicine, Columbia University Medical Center, New York (W.K.C.).</aff>
                <aff id="aff14"><label>14</label>Cardiology, Children’s Hospital of Philadelphia, Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia (E.G.).</aff>
                <aff id="aff15"><label>15</label>Pediatrics, University of Rochester Medical Center (G.A.P.).</aff>
                <aff id="aff16"><label>16</label>Genetics, Yale University School of Medicine, New Haven (R.P.L., M.B.).</aff>
                <aff id="aff17"><label>17</label>Laboratory of Human Genetics and Genomics, Rockefeller University, New York (R.P.L.).</aff>
                <aff id="aff18"><label>18</label>Pediatrics, Yale University School of Medicine, New Haven (M.B.).</aff>
                <aff id="aff19"><label>19</label>Molecular Medicine Program, University of Utah, Salt Lake City (H.J.Y.).</aff>
                <aff id="aff20"><label>20</label>Gladstone Institutes, San Francisco, CA (B.G.B.).</aff>
                <aff id="aff21"><label>21</label>Division of Cardiovascular Medicine, Brigham and Women’s Hospital (Y.K.).</aff>
                <aff id="aff22"><label>22</label>Biomedicine (S.V., T.A.), University of Bergen, N-5020 Bergen, Norway.</aff>
                <aff id="aff23"><label>23</label>Biological Sciences (S.V., T.A.), University of Bergen, N-5020 Bergen, Norway.</aff>
                <aff id="aff24"><label>24</label>Donnelly Centre for Cellular and Biomolecular Research, Toronto, Canada (S.V.).</aff>
                <aff id="aff25"><label>25</label>Surgery, Haukeland University Hospital, N-5021 Bergen, Norway (T.A.).</aff>
              </contrib-group>
              <author-notes>
                <corresp id="c1">Correspondence to: Jonathan G. Seidman, PhD, New Research Bldg Room 256, 77 Ave Louis Pasteur, Boston, MA 02115. Email <email xlink:href="seidman@genetics.med.harvard.edu">seidman@genetics.med.harvard.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>09</day>
                <month>2</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <day>16</day>
                <month>4</month>
                <year>2021</year>
              </pub-date>
              <volume>128</volume>
              <issue>8</issue>
              <fpage>1156</fpage>
              <lpage>1169</lpage>
              <history>
                <date date-type="received">
                  <day>10</day>
                  <month>4</month>
                  <year>2020</year>
                </date>
                <date date-type="rev-recd">
                  <day>3</day>
                  <month>2</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>8</day>
                  <month>2</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2021 The Authors.</copyright-statement>
                <copyright-year>2021</copyright-year>
                <license>
                  <ali:license_ref specific-use="pmc" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p><italic>Circulation Research</italic> is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution Non-Commercial-NoDerivs</ext-link> License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.</license-p>
                </license>
                <license>
                  <license-p>This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="res-128-1156.pdf"/>
              <abstract abstract-type="toc">
                <p>Supplemental Digital Content is available in the text.</p>
              </abstract>
              <abstract>
                <sec>
                  <title>Rationale:</title>
                  <p>NAA15 (N-alpha-acetyltransferase 15) is a component of the NatA (N-terminal acetyltransferase complex). The mechanism by which NAA15 haploinsufficiency causes congenital heart disease remains unknown. To better understand molecular processes by which NAA15 haploinsufficiency perturbs cardiac development, we introduced <italic>NAA15</italic> variants into human induced pluripotent stem cells (iPSCs) and assessed the consequences of these mutations on RNA and protein expression.</p>
                </sec>
                <sec>
                  <title>Objective:</title>
                  <p>We aim to understand the role of NAA15 haploinsufficiency in cardiac development by investigating proteomic effects on NatA complex activity and identifying proteins dependent upon a full amount of NAA15.</p>
                </sec>
                <sec>
                  <title>Methods and Results:</title>
                  <p>We introduced heterozygous loss of function, compound heterozygous, and missense residues (R276W) in iPSCs using CRISPR/Cas9. Haploinsufficient <italic>NAA15</italic> iPSCs differentiate into cardiomyocytes, unlike <italic>NAA15</italic>-null iPSCs, presumably due to altered composition of NatA. Mass spectrometry analyses reveal ≈80% of identified iPSC NatA targeted proteins displayed partial or complete N-terminal acetylation. Between null and haploinsufficient <italic>NAA15</italic> cells, N-terminal acetylation levels of 32 and 9 NatA-specific targeted proteins were reduced, respectively. Similar acetylation loss in few proteins occurred in <italic>NAA15</italic> R276W induced pluripotent stem cells. In addition, steady-state protein levels of 562 proteins were altered in both null and haploinsufficient <italic>NAA15</italic> cells; 18 were ribosomal-associated proteins. At least 4 proteins were encoded by genes known to cause autosomal dominant congenital heart disease.</p>
                </sec>
                <sec>
                  <title>Conclusions:</title>
                  <p>These studies define a set of human proteins that requires a full NAA15 complement for normal synthesis and development. A 50% reduction in the amount of NAA15 alters levels of at least 562 proteins and N-terminal acetylation of only 9 proteins. One or more modulated proteins are likely responsible for NAA15-haploinsufficiency mediated congenital heart disease. Additionally, genetically engineered induced pluripotent stem cells provide a platform for evaluating the consequences of amino acid sequence variants of unknown significance on NAA15 function.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>congenital heart defects</kwd>
                <kwd>haploinsufficiency</kwd>
                <kwd>induced pluripotent stem cells</kwd>
                <kwd>proteins</kwd>
                <kwd>proteomics</kwd>
                <kwd>ribosomes</kwd>
              </kwd-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>OPEN-ACCESS</meta-name>
                  <meta-value>TRUE</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>SDC</meta-name>
                  <meta-value>T</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <p>
              <bold>Editorial, see p <related-article related-article-type="companion" id="ra1" vol="128" page="1170" issue="8" ext-link-type="pmc">1170</related-article></bold>
            </p>
            <p>
              <bold>In This Issue, see p <related-article related-article-type="article-reference" id="ra2" vol="128" page="1119" issue="8" ext-link-type="pmc">1119</related-article></bold>
            </p>
            <p>
              <bold>Meet the First Author, see p <related-article related-article-type="article-reference" id="ra3" vol="128" page="1120" issue="8" ext-link-type="pmc">1120</related-article></bold>
            </p>
            <p>Congenital heart disease (CHD), which affects about 1% of newborns, reflects defects in the developmental program of the heart.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> Defining the genetic causes of CHD will provide new insights into mechanisms of cardiac development that may eventually benefit patients with CHD and their families. Whole exome sequencingof CHD probands and their parents have enabled the identification of recurrent damaging variants in multiple genes that likely are critical for normal cardiac development.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> Functional studies are necessary to further define these gene functions and the pathogenetic mechanisms of damaging variants. While loss of function (LoF) variants infer that haploinsufficiency of the encoded protein contributes to CHD, the consequence of missense variants on protein function are less readily interpreted, often leading to classification of these as variants of unknown significance although some may contribute to the CHD.<sup><xref rid="R2" ref-type="bibr">2</xref></sup></p>
            <p>We previously reported 2 patients with CHD with de novo heterozygous LoF variants in <italic>NAA15</italic> (N-alpha-acetyltransferase 15), which encodes a protein subunit of the NAT (N-terminal [Nt] acetyltransferase) complex.<sup><xref rid="R2" ref-type="bibr">2</xref>–<xref rid="R4" ref-type="bibr">4</xref></sup> In addition to CHD, these patients had extra-cardiac disorders including neurodevelopmental deficits.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup> Prior studies have reported damaging <italic>NAA15</italic> variants in patients with other congenital malformations and neurodevelopmental abnormalities.<sup><xref rid="R5" ref-type="bibr">5</xref>–<xref rid="R7" ref-type="bibr">7</xref></sup></p>
            <p>Acetylation of the N-terminus of proteins is a prevalent modification that occurs in ≈85% of yeast and human proteins.<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref></sup> The effect of Nt-acetylation on proteins is diverse and includes changes to protein stability, complex formation, protein folding, and aggregation.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> The NatA complex, one of 8 NAT types, is essential in most, if not all, eukaryotes and is responsible for the majority of Nt-acetylation.<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R11" ref-type="bibr">11</xref></sup> This complex binds the ribosome and was shown to acetylate nascent polypeptide chains at specific Nt amino acids (Ser-, Thr-, Ala-, Val-, Gly-, and Cys-) after the initiating methionine is removed.<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R13" ref-type="bibr">13</xref></sup> The NatA complex is formed by the catalytic subunit NAA10 and the auxiliary unit NAA15. HYPK (Huntingtin interacting protein K) is a chaperone protein that attaches to the NatA complex along with subunit NAA50.<sup><xref rid="R14" ref-type="bibr">14</xref>–<xref rid="R17" ref-type="bibr">17</xref></sup> NAA50 also forms part of the NatE complex, which displays a distinct substrate specificity compared with NatA.<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R18" ref-type="bibr">18</xref></sup> NAA15 is a subunit of both the NatA and NatE complexes, and its role is to position the catalytic subunits in close vicinity to the nascent polypeptides; in the case of NAA10, it also modulates its substrate specificity.<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R19" ref-type="bibr">19</xref>–<xref rid="R21" ref-type="bibr">21</xref></sup> Additionally, NAA15 interaction with NAA10 and HYPK has been implicated in regulation of protein folding and Nt-acetylation fidelity.<sup><xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R22" ref-type="bibr">22</xref></sup> Abnormal NatA complex function has been previously associated with human cancers and neurological disorders.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup> To date, the relationship between Nt-acetylation, NAA15, and CHD has not been investigated.</p>
            <p>We studied human isogenic induced pluripotent stem cell (iPSC) lines that were engineered to contain <italic>NAA15</italic> variants identified in patients with CHD and predicted to be damaging. We evaluated whether iPSCs with NAA15 variants differentiated into cardiomyocytes. By assessing both Nt-acetylation and protein levels by mass spectrometry (MS), we demonstrate that NAA15 haploinsufficiency perturbs normal function of undifferentiated iPSCs. We identify proteins that require the full complement of NAA15 to preserve the integrity of these stem cells for cardiac development.</p>
            <sec sec-type="methods">
              <title>Methods</title>
              <sec sec-type="data-availability">
                <title>Data Availability</title>
                <p>All data and materials have been made publicly available. Further details are provided in the Major Resources Table located in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>.</p>
              </sec>
              <sec>
                <title>Study Cohort With CHD</title>
                <p>CHD subjects (n=4511) were recruited to the Congenital Heart Disease Network Study of the Pediatric Cardiac Genomics Consortium (CHD GENES: URL: <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov">https://www.clinicaltrials.gov</ext-link>; Unique identifier: NCT01196182) or the DNA biorepository of the Single Ventricle Reconstruction trial after approval from Institutional Review Boards as previously described.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> All subjects or their parents provided informed consent. Clinical diagnoses, including cardiac and noncardiac congenital anomalies, were obtained from review of patient charts and family interview.</p>
              </sec>
              <sec>
                <title>CRISPR Gene Editing and Mutation Confirmation</title>
                <p>Isogenic personal genome project 1 iPSCs were modified using CRISPR/Cas9 technology to create <italic>NAA15</italic> LoF or missense mutation cell lines.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> Further details provided in Methods in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>.</p>
              </sec>
              <sec>
                <title>Label-Free Quantitative Shotgun Proteomics and Data Analysis</title>
                <p>Two independent iPSC lines of both wild type (WT) cells and <italic>NAA15</italic> mutant cells were grow in 10 cm petri dishes until near confluency. iPSCs were detached and using Accutase (Millipore) and collected in 15 cm centrifuge tubes. Cells were centrifuged (Beckman) in a 15 mL tube at 1000 rpm for 5 minutes. Cells were washed with PBS and pelleted by centrifugation. Eight samples of each genotype was collected, and a total of 24 samples were prepared for LC-MS/MS/ analysis. Further details provided in Methods in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>.</p>
                <p>The MS proteomics data have been deposited to the ProteomeXchange Consortium (<ext-link ext-link-type="uri" xlink:href="http://proteomecentral.proteomexchange.org">http://proteomecentral.proteomexchange.org</ext-link>) via the PRIDE partner repository with the data set identifiers PXD017672 and PXD018013.</p>
              </sec>
              <sec>
                <title>Bioinformatic Analysis and Gene Ontology Analysis</title>
                <p>Gene ontology annotation proteome was derived using the R package clusterProfiler.<sup><xref rid="R28" ref-type="bibr">28</xref></sup> Proteins were classified by Gene ontology annotation based on biological process, molecular function, and cellular component. Quantified proteins detected by MS of iPSCs were used as a background and other parameters with default. The <italic>P</italic> values were adjusted by Bonferroni correction for multiple testing.</p>
              </sec>
              <sec>
                <title>Statistics</title>
                <p>Single comparisons were analyzed by using the Student <italic>t</italic> test, with significance defined as <italic>P</italic>&lt;0.05. Multiple comparisons between genotypes were analyzed using 1-way ANOVA with post hoc Tukey HSD, with significance defined as <italic>P</italic>&lt;0.05. For proteomics, pairwise SAM <italic>t</italic> tests (or pairwise statistical testing using the SAM method<sup><xref rid="R29" ref-type="bibr">29</xref></sup>) were performed and significant hits determined using as cutoff values a permutation based false discovery rate (FDR) of 0.01 (1000 permutations) and a background variance parameter s0 of 1. For all experiments analyzed for statistical significance, only within-test corrections were made.</p>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>Results</title>
              <sec>
                <title>NAA15 Variants Are Associated With CHD and Other Extra Cardiac Anomalies</title>
                <p>Whole exome sequencing of 4511 patients with CHD <sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R4" ref-type="bibr">4</xref></sup> identified 4 subjects with a rare LoF variant (allele frequency &lt;0.00005) in the <italic>NAA15</italic> gene, resulting in NAA15 haploinsufficiency (Figure <xref ref-type="fig" rid="F1">1</xref>A). Parental analyses indicated that 3 of these LoF variants (p.Ser761*, p.Lys336Lys fs*6, and p.Arg470*) arose de novo in the probands.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R4" ref-type="bibr">4</xref></sup> The inheritance of the p.Ala718fs variant is uncertain, as parental samples were unavailable. Among ≈125 000 subjects in the gnomAD database,<sup><xref rid="R12" ref-type="bibr">12</xref></sup> 14 <italic>NAA15</italic> LoF variants are reported, inferring an 8.9-fold higher frequency of <italic>NAA15</italic> LoF variants in CHD probands (<italic>P</italic>=0.002).</p>
                <fig id="F1" orientation="portrait" position="float">
                  <label>Figure 1.</label>
                  <caption>
                    <p><bold><italic>NAA15</italic> variants discovered in patients with congenital heart disease patients.</bold><bold>A</bold>, Schematic diagram of the <italic>NAA15</italic> (N-alpha-acetyltransferase 15) gene. The <italic>NAA15</italic> gene consists of tetracopeptide repeats (blue) essential for interaction with the NatA (N-terminal acetyltransferase) complex subunit NAA10 and a HYPK (Huntingtin interacting protein K) interacting domain at the C terminus. Location of variants identified in patients with congenital heart disease (CHD; loss of function [LoF] variants are underlined) and CRISPR/Cas9-derived variants in induced pluripotent stem cell (iPSCs; magenta) are shown. <bold>B</bold>, The subunit composition of NatA and NatE complexes. NAA15 is the auxiliary unit for both complexes. <bold>C</bold>, Table of cardiovascular and neuronal clinical phenotypes of patients with CHD. *indicates LoF variants.</p>
                  </caption>
                  <graphic xlink:href="res-128-1156-g001"/>
                </fig>
                <p>The CHD phenotypes included tetralogy of Fallot, heterotaxy with d-looped ventricles, transposition of the great arteries, and hypoplastic left or right heart syndrome (Figure <xref ref-type="fig" rid="F1">1</xref>C and Table I in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). In addition to cardiac anomalies, all 4 patients with CHD with a <italic>NAA15</italic> LoF variant had extracardiac anomalies including seizures, neurobehavioral, ophthalmologic, auditory, or orthopedic disorders (Figure <xref ref-type="fig" rid="F1">1</xref>C and Table I in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>).<sup><xref rid="R5" ref-type="bibr">5</xref></sup></p>
                <p>We also identified 15 very rare (allele frequency &lt;1.0×10<sup>−5</sup>e-5 or absent from the gnomAD database<sup><xref rid="R12" ref-type="bibr">12</xref></sup>) inherited <italic>NAA15</italic> missense variants among these 4511 patients with CHD (Figure IA and Table I in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). In addition, one missense variant, R276W (Figure <xref ref-type="fig" rid="F1">1</xref>A and Figure IA and IB in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>), could not be assessed for inheritance. The frequency of rare missense alleles in the Pediatric Cardiac Genomics Consortium (PCGC) cohort was 0.0035 (n=16 of 4511 CHD probands), significantly higher than the frequency observed among ≈115 000 Gnomad subjects (frequency, 0.002; n=198; <italic>P</italic>=0.02; odds ratio, 1.8). CHD probands with rare <italic>NAA15</italic> missense variants had notably fewer extracardiac anomalies than CHD probands with <italic>NAA15</italic> LoF variants (Table I in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). Hence, despite the observation that these very rare <italic>NAA15</italic> missense variants were transmitted from an unaffected parent, we suspected that some of them contribute to CHD.</p>
              </sec>
              <sec>
                <title>Genetically Engineered iPSCs Model NAA15 Haploinsufficiency</title>
                <p>We introduced <italic>NAA15</italic> variants into the iPSC line, personal genome project 1, using CRISPR/Cas9 gene editing (see Methods in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>) to create human iPSCs with reduced or no NAA15 protein. Two independent cell lines were constructed with each genotype <italic>NAA15</italic><sup>−/−</sup>, <italic>NAA15</italic><sup>+/−</sup>, and <italic>NAA15</italic><sup><italic>+/R276W</italic></sup> (Figure <xref ref-type="fig" rid="F1">1</xref>A, Figure IA through IC and Table II in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>) and studied as detailed below. <italic>NAA15</italic> variants in iPSCs were confirmed both by Sanger sequencing and next generation sequencing of PCR amplified products (Figure IIA through IIC in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>).</p>
                <p>RNA expression levels for each of the 2 independent iPSC lines in <italic>NAA15</italic><sup>+/+</sup> and <italic>NAA15</italic>-mutant iPSCs, were first characterized by RNAseq. <italic>NAA15</italic> mRNA levels were reduced by 56% and 24% in the <italic>NAA15</italic><sup>+/−</sup> and <italic>NAA15</italic><sup><italic>+/R276W</italic></sup> iPSCs, respectively (Figure <xref ref-type="fig" rid="F2">2</xref>A and Table III in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). There was a 99% decrease in <italic>NAA15</italic> mRNA in <italic>NAA15</italic><sup>−/−</sup> iPSCs, suggesting that these variants triggered nonsense-mediated decay (Figure <xref ref-type="fig" rid="F2">2</xref>A). We performed MS-based shotgun proteomics in at least 3 replicates for each of the 2 independent lines. NAA15 protein was near-normal levels in <italic>NAA15</italic><sup>+/−</sup> iPSCs but absent from <italic>NAA15</italic><sup>−/−</sup> iPSCs (Figure <xref ref-type="fig" rid="F2">2</xref>B). The amount of NAA15 protein detected by MS in <italic>NAA15</italic><sup>+/−</sup> iPSCs could represent a proportion of truncated NAA15 polypeptides. To confirm this hypothesis, NAA15 protein levels were measured in 2 independent biological replicates of both WT and NAA15 mutant iPSCs by Western blotting (Figure IID and IIE in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>), which supported this conclusion. NAA15 protein was reduced in <italic>NAA15</italic><sup>+/−</sup> iPSCs by about 50%, and full length NAA15 protein was not detectable in <italic>NAA15</italic><sup>−/−</sup> iPSCs (Figure IID and IIE in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>).</p>
                <fig id="F2" orientation="portrait" position="float">
                  <label>Figure 2.</label>
                  <caption>
                    <p><bold><italic>NAA15</italic><sup>+/−</sup> and <italic>NAA15</italic><sup><italic>+/R276W</italic></sup> induced pluripotent stem cells (iPSCs) develop into cardiomyocytes, while <italic>NAA15</italic> (N-alpha-acetyltransferase 15) null iPSCs have reduced viability.</bold><bold>A</bold>, Graph shows RNA expression of the NatA (N-terminal acetyltransferase) components in <italic>NAA15</italic>-mutant iPSCs. <italic>NAA15</italic> RNA levels are significantly lowered in iPS cells with <italic>NAA15</italic><sup>+/−</sup> and <italic>NAA15</italic><sup>−/−</sup> variants compared with wildtype iPSCs. Data was collected from 2 independent cell lines for each genotype and as technical replicates for selected lines. Total cell lines analyzed: NAA15<sup>+/+</sup> (n=3), NAA15<sup>−/−</sup> (n=4), NAA15<sup>+/−</sup> (n=4), and NAA15<sup>+/R276W</sup> (n=2). Significance of differences between NAA15 mutant iPSCs and wildtype iPSCs were evaluated by Student <italic>t</italic> tests, <italic>P</italic>&lt;0.05 (<italic>P</italic> values were adjusted by Bonferroni correction; only significant adjusted <italic>P</italic> values are displayed). All data points are presented and plotted as mean±SEM. <bold>B</bold>, Graph represents fold change ratios of relative protein levels in NAA15 mutant iPSCs compared with wildtype iPSCs for Nat complex subunits. Relative protein abundance was quantified by MaxLFQ algorithms integrated in the MaxQuant software. Data was collected from two independent undifferentiated iPS cell lines for each NAA15 mutant genotype and as technical replicates for each cell line. Total cell lines analyzed: NAA15<sup>+/−</sup> (n=8), NAA15<sup>−/−</sup> (n=8), NAA15<sup>+/−</sup> (n=7), and NAA15<sup>+/R276W</sup> (n=8). Significant changes indicated by <italic>P</italic> values were calculated using pairwise comparison SAM <italic>t</italic> test method and a permutation based false discovery rate (FDR) of 0.01 (1000 permutations) as cutoff values with a background variance parameter s0 of 1. All data points are presented and plotted as mean±SEM. <bold>C</bold>, Representative images of <italic>NAA15</italic><sup>+/+</sup> iPSCs and <italic>NAA15</italic><sup>+/−</sup> iPSCs stained with cardiac troponin T antibody (green), α-actinin (magenta), and DAPI for nuclei (blue). A representative image for each cell type is presented. Normal sarcomeres were observed in both NAA15 mutant and wildtype iPSC-CMs. Magnification, 60×; scale bar 25um.</p>
                  </caption>
                  <graphic xlink:href="res-128-1156-g002"/>
                </fig>
                <p>Because NAA15 is normally associated with components NAA10, HYPK, and NAA50<sup><xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref></sup> (Figure <xref ref-type="fig" rid="F1">1</xref>B), we assessed the levels of these proteins in the mutant iPSCs using MS. Both <italic>NAA15</italic><sup>−/−</sup> and <italic>NAA15</italic><sup>+/−</sup> iPSCs showed decreased protein levels of NAA10 (Figure <xref ref-type="fig" rid="F2">2</xref>B). NAA50, the catalytic unit of NatE and binding partner of NAA15 protein, was reduced in <italic>NAA15</italic><sup>−/−</sup> iPSCs. Significant reduction of the NAA50 protein did not occur in <italic>NAA15</italic><sup>+/−</sup> iPSCs (Figure <xref ref-type="fig" rid="F2">2</xref>B). Noticeably, HYPK, a NAA15 binding partner and subunit of the NatA complex was significantly reduced in both <italic>NAA15</italic><sup>+/−</sup> and <italic>NAA15</italic><sup>−/−</sup> iPSCs (Figure <xref ref-type="fig" rid="F2">2</xref>B).</p>
                <p>We further explored the functional effects of <italic>NAA15</italic><sup>+/−</sup> and <italic>NAA15</italic><sup><italic>+/R276W</italic></sup> using a yeast assay in which the hNatA (human NatA complex) functionally replaced yeast NatA, as shown by complementation of growth phenotypes with partial rescue of the NatA-specific Nt-acetylome.<sup><xref rid="R8" ref-type="bibr">8</xref></sup> HsNatA D335fs and S761* failed to rescue the temperature-sensitive growth phenotype of yNatAΔ (Figure IIIA through IIIC in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>), suggesting that <italic>NAA15</italic><sup>+/−</sup> results in impaired NatA functionality. However, in this yeast assay, human HsNatA R276W rescued yeast growth suggesting at least partial NatA function in yeast (Figure IIIC in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). Noticeably, <italic>Schizosaccharomyces pombe</italic> NAA15 has a tryptophan residue at position 276 while all mammals have an arginine residue, which suggests that this residue is functionally important in human cells. As such, we suggest that rescue of yeast growth experiments might not fully provide functional assessments of mutant human NAA15 proteins.</p>
              </sec>
              <sec>
                <title>NAA15<sup>+/−</sup> and NAA15<sup>+/R276W</sup> iPSCs Develop Into Contractile Cardiomyocytes, While NAA15<sup>−/−</sup> iPSCs Have Reduced Viability</title>
                <p>To test whether <italic>NAA15</italic> variants have an effect on iPSC maturation, 2 independent iPSC lines for each genotype (<italic>NAA15</italic><sup>−/−</sup>, <italic>NAA15</italic><sup>+/−</sup>, and <italic>NAA15</italic><sup><italic>+/R276W</italic></sup>) were differentiated into cardiomyocytes using a 13-day differentiation protocol to assess for the development and contractility of sarcomeres.<sup><xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R31" ref-type="bibr">31</xref></sup> Both <italic>NAA15</italic><sup>+/−</sup> and <italic>NAA15</italic><sup><italic>+/R276W</italic></sup> cells differentiated into cardiomyocytes (Figure <xref ref-type="fig" rid="F2">2</xref>C, a and b), however, <italic>NAA15</italic><sup>−/−</sup> iPSCs grew slowly (data not shown) and failed to differentiate. Cell viability of <italic>NAA15</italic>-mutant iPSCs was assessed (see Methods in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). Similar to observations reported in <italic>NAA15</italic>/NatA yeast knockout and human knockdown cells,<sup><xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R32" ref-type="bibr">32</xref>–<xref rid="R34" ref-type="bibr">34</xref></sup>
<italic>NAA15</italic><sup>−/−</sup> iPSCs had significantly retarded growth and cell death (<italic>P</italic>=0.001; average cell death is 12% in NAA15<sup>+/+</sup> iPSCs versus 32% in <italic>NAA15</italic><sup>−/−</sup> iPSCs, n=2). <italic>NAA15</italic><sup>+/−</sup> iPSC-derived cardiomyocytes (iPSC-CMs) were stained with cardiac troponin T and actinin antibodies to visualize sarcomere structures (Figure <xref ref-type="fig" rid="F2">2</xref>C, a and b). <italic>NAA15</italic> mutant cell sarcomeres were indistinguishable from WT cell sarcomeres (Figure <xref ref-type="fig" rid="F2">2</xref>C, a and b and Figure IV and Table IV in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>).</p>
                <p>Contractility of <italic>NAA15</italic><sup>+/−</sup> and <italic>NAA15</italic><sup><italic>+/R276W</italic></sup> iPSC-CMs was monitored by live image analysis (Movies I and II in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). Two biological replicates of <italic>NAA15</italic> mutant iPSC-CMs and one of 2 biological replicates for WT iPSC-CMs were incubated with GFP (green fluorescent protein)-actinin lentivirus to enable high fidelity tracking of sarcomere function<sup><xref rid="R35" ref-type="bibr">35</xref></sup>(Movies III through V in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). The lengths of GFP-labeled sarcomeres were measured during the contractile cycle. Contractile measurements of unloaded (ie, sarcomeres that were not working against resistance) demonstrated no difference in rates of sarcomere shortening or contraction between mutant and WT cells (Figure VA in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). To better recapitulate native cardiomyocyte architecture and mechanics, the function of loaded sarcomeres from these cells grown as 3-dimensional micro-tissue structures,<sup><xref rid="R36" ref-type="bibr">36</xref>,<xref rid="R37" ref-type="bibr">37</xref></sup> where sarcomeres work against resistance, were created from WT iPSC-CMs and 2 biological replicates of <italic>NAA15</italic> mutant iPSC-CMs (Movies VI through VIII in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). In contrast to unloaded 2-dimensional tissue sarcomere function, image analysis show loaded <italic>NAA15</italic><sup>+/−</sup> iPSC-CM sarcomeres exhibited a smaller percent contraction than WT iPSC-CM sarcomeres (Figure VB in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>).</p>
              </sec>
              <sec>
                <title>Nt-acetylation in NAA15 Haploinsufficient, Null, and R276W Missense iPSCs</title>
                <p>We studied Nt-acetylation of 2 biological replicates in iPSCs with <italic>NAA15</italic> variants and WT using a MS-based Nt enrichment assay.<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R38" ref-type="bibr">38</xref>–<xref rid="R40" ref-type="bibr">40</xref></sup> NatA acetylates N-termini containing Ser-, Thr-, Ala-, Val-, Gly-, or Cys.<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R12" ref-type="bibr">12</xref></sup> We identified a total of 989 previously annotated N-termini<sup><xref rid="R41" ref-type="bibr">41</xref></sup> in one or both of the 2 independent cell lines for WT and <italic>NAA15</italic> mutant iPSCs (Table V in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>); ≈650 N-termini peptides were identified in each cell line (Tables V and VI in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). NatA targeted sequences represented ≈60% of the 989 detected N-termini peptides (Tables V and VI in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>); no Cys-starting peptides were detected. In <italic>NAA15</italic><sup>+/+</sup> iPSCs, we observed 17 Nt peptides that were partially acetylated (10%–95%) and 359 with complete (&gt;95%) Nt-acetylation (Figure <xref ref-type="fig" rid="F3">3</xref>A and Tables V and VI in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). Of the completely or partially Nt-acetylated peptides,<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup> 98% have an alanine, threonine, or serine at position 2 (Figure <xref ref-type="fig" rid="F3">3</xref>B and Tables VI and VII in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). However, peptides with partial acetylation have a much higher fraction of Nt glycine or valine residues (Figure <xref ref-type="fig" rid="F3">3</xref>C and Tables VI and VII in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). The preference for acetylation of proteins with Nt alanine and serine residues was preserved in <italic>NAA15</italic>-mutant iPSCs as observed in previous studies (Tables VI and VII in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>).<sup><xref rid="R23" ref-type="bibr">23</xref></sup></p>
                <fig id="F3" orientation="portrait" position="float">
                  <label>Figure 3.</label>
                  <caption>
                    <p><bold>N-terminal acetylation in <italic>NAA15</italic><sup>+/−</sup> and <italic>NAA15</italic><sup>−/−</sup> induced pluripotent stem cells (iPSCs).</bold><bold>A</bold>, N-terminal peptides acetylated in <italic>NAA15</italic><sup>+/+</sup> iPSCs are categorized by NAT-type substrate specificity. NatA (N-terminal acetyltransferase) targets are displayed according to percent Nt-acetylation; Nt-acetylation &gt;10% highlighted in gold and Nt-acetylation &lt;10% highlighted in light gold. <bold>B</bold> and <bold>C</bold>, The number of Nt-acetylated NatA-type N-terminal peptides represented by residues A, G, S, T, or V in NAA15 mutant and wildtype iPSCs. Data is displayed as the absolute number of peptides measured from the sum of 2 biological replicates for each genotype. Alanine and serine residues are preferentially acetylated in peptides with &gt;10% Nt-acetylation; glycine and valine residues are representative of N-termini with &lt;10% Nt-acetylation. Primary peptide summary provided in Table V in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>. There were no statistically significant differences between genotypes (hypergeometric test; data not shown). <bold>D–F</bold>, Representative scatter plots display the correlation of the degrees of Nt-acetylation of all N-termini identified as NatA targets in <italic>NAA15</italic><sup>−/−</sup>, <italic>NAA15</italic><sup>+/−</sup>, <italic>NAA15</italic><sup><italic>+/R276W</italic></sup>, and <italic>NAA15</italic><sup>+/+</sup> iPSCs. Each plot compares <italic>NAA15</italic> (N-alpha-acetyltransferase 15) mutant iPSCs to wildtype iPSCs. Differentially acetylated N-termini are found below the line of identity (y intercept=0, slope=1). Peptides lose acetylation moieties in <italic>NAA15</italic>-mutant iPSCs. <italic>NAA15</italic><sup>−/−</sup> iPSCs have the largest number of peptides (n=32) with reduced Nt-acetylation. There are N-termini with reduced N-terminal acetylation in <italic>NAA15</italic><sup>+/−</sup> iPSCs (n=9) and <italic>NAA15</italic><sup><italic>+/R276W</italic></sup> iPSCs (n=8). Decreased protein expression changes are highlighted in red. COPS3 indicates COP9 signalosome complex subunit 3; DDX54, ATP-dependent RNA helicase; NDUFB6, NADH dehydrogenase (ubiquinone) 1β subcomplex subunit 6; PABPN1, polyadenylate-binding protein 2; PPWD1, peptidyl-prolyl isomerase domain and WD repeat-containing protein 1; and VPS4A, vacuolar protein sorting-associated protein 4.</p>
                  </caption>
                  <graphic xlink:href="res-128-1156-g003"/>
                </fig>
                <p>Protein Nt-acetylation in <italic>NAA15</italic> mutant iPSCs was compared with Nt-acetylation in WT iPSCs. Only a limited number of putative NatA-type N-termini substrates had &gt;10% difference in acetylation between wild type and mutant iPSCs (Figure <xref ref-type="fig" rid="F3">3</xref>, Table <xref rid="T1" ref-type="table">1</xref>, and Figure VI in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). In <italic>NAA15</italic><sup>−/−</sup> iPSCs 32 proteins showed these changes (Figure <xref ref-type="fig" rid="F3">3</xref>B through <xref ref-type="fig" rid="F3">3</xref>D and Table <xref rid="T1" ref-type="table">1</xref>). Notably, all proteins that had partial acetylation in WT iPSCs lacked Nt-acetylation in <italic>NAA15</italic><sup>−/−</sup>. Nine of these proteins were altered in <italic>NAA15</italic><sup>+/−</sup> iPSCs and 8 had altered Nt-acetylation in <italic>NAA15</italic><sup>+/R276W</sup> iPSCs (Figure <xref ref-type="fig" rid="F3">3</xref>E and <xref ref-type="fig" rid="F3">3</xref>F, Table <xref rid="T1" ref-type="table">1</xref>).</p>
                <table-wrap id="T1" orientation="portrait" position="float">
                  <label>Table 1.</label>
                  <caption>
                    <p>Proteins With Altered N-Terminal Acetylation in Wildtype and NAA15 Mutant iPSCs*</p>
                  </caption>
                  <graphic xlink:href="res-128-1156-g004"/>
                </table-wrap>
                <p>All proteins with reduced acetylation in mutant iPSCs displayed NatA-type substrate specificity (Tables <xref rid="T1" ref-type="table">1</xref> and <xref rid="T2" ref-type="table">2</xref>, Table V in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). Greater than 50% of proteins with altered Nt-acetylation had an alanine residue at position 2 and &gt;30% also had an alanine residue at position 3 (Table <xref rid="T2" ref-type="table">2</xref>).<sup><xref rid="R23" ref-type="bibr">23</xref></sup> The distribution of N-terminal residues in proteins with altered Nt-acetylation did not differ significantly from the distribution of N-terminal residues in proteins with unchanged N-terminal acetylation in these cells (not shown). We deduced that <italic>NAA15</italic> variants or deficiency altered N-terminal acetylation in a small number of NatA substrate proteins and with no preference for an extended N-terminal amino acid substrate specificity.</p>
                <table-wrap id="T2" orientation="portrait" position="float">
                  <label>Table 2.</label>
                  <caption>
                    <p>Second and Third Amino Acid Identities of Peptides With Altered Nt-Acetylation in NAA15 Mutant iPSCs</p>
                  </caption>
                  <graphic xlink:href="res-128-1156-g005"/>
                </table-wrap>
                <p>We noticed that some proteins reduced in Nt-acetylation (Figure <xref ref-type="fig" rid="F3">3</xref>D) have functions in cellular proliferation and survival,<sup><xref rid="R42" ref-type="bibr">42</xref>–<xref rid="R46" ref-type="bibr">46</xref></sup> perhaps accounting for the deficits in growth and viability of <italic>NAA15</italic><sup>−/−</sup> iPSC.<sup><xref rid="R41" ref-type="bibr">41</xref>–<xref rid="R46" ref-type="bibr">46</xref></sup> To understand whether the change in Nt-acetylation status compromised the function of these proteins and contributed to the phenotype of <italic>NAA15</italic><sup>−/−</sup> iPSCs, we used a combination of shotgun MS-based proteomics and pairwise comparison by SAM <italic>t</italic> test (FDR=0.01; Tables VIII through X in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). Nine proteins with reduced acetylation correlated with changes in protein expression in <italic>NAA15</italic><sup>−/−</sup> iPSCs (Figure <xref ref-type="fig" rid="F3">3</xref>D and <xref ref-type="fig" rid="F4">4</xref>A). Among these, measurable acetylation occurred in 3 proteins in <italic>NAA15</italic><sup>+/−</sup> and in one protein in <italic>NAA15</italic><sup><italic>+/R276W</italic></sup> iPSCs (Figure <xref ref-type="fig" rid="F3">3</xref>E and <xref ref-type="fig" rid="F3">3</xref>F).</p>
                <fig id="F4" orientation="portrait" position="float">
                  <label>Figure 4.</label>
                  <caption>
                    <p><bold>Proteins differentially expressed in <italic>NAA15</italic><sup>+/−</sup> and <italic>NAA15</italic><sup>−/−</sup> induced pluripotent stem cells (iPSCs).</bold><bold>A</bold>, Scatterplot displays log2 fold changes of differentially expressed proteins in <italic>NAA15</italic><sup>+/−</sup> and <italic>NAA15</italic><sup>−/−</sup> iPSCs compared with wildtype (WT) iPSCs. Approximately 1200 proteins are differentially expressed, 9 and 3 proteins of which have reduced Nt-acetylation in NAA15<sup>−/−</sup> iPSCs and NAA15<sup>+/−</sup> iPSCs, respectively. Data was collected from 2 independent undifferentiated iPS cell lines for each NAA15 (N-alpha-acetyltransferase 15) mutant genotype and at least 3 technical replicates for each sample. <bold>B</bold>, Comparison of differentially expressed proteins in <italic>NAA15</italic><sup>−/−</sup> and <italic>NAA15</italic><sup>+/−</sup> iPSCs. Differential expression was considered for log2 fold change |1|. Identified proteins: 5196, quantified proteins: 3911 proteins detected by mass spectrometry (<bold>C</bold>) gene ontology (GO) enrichment of differentially expressed proteins in both <italic>NAA15</italic><sup>−/−</sup> and <italic>NAA15</italic><sup>+/−</sup> iPSCs. A total of 41 proteins are localized to the ribosome. Raw <italic>P</italic> value presented in data table. <bold>D</bold>, Bar graph represents log2 fold change of ribosomal proteins that are differentially expressed in both <italic>NAA15</italic><sup>−/−</sup> and <italic>NAA15</italic><sup>+/−</sup> iPSCs.</p>
                  </caption>
                  <graphic xlink:href="res-128-1156-g006"/>
                </fig>
              </sec>
              <sec>
                <title>Altered Protein Expression Due to NAA15 Haploinsufficiency or Deficiency</title>
                <p>Using shotgun proteomics, we studied 2 independent undifferentiated iPSC lines for each <italic>NAA15</italic> mutant genotype and at least 3 technical replicates for each sample to assess protein levels (Table VIII in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). Among 5196 proteins identified by MS, extracts from NAA15+/- iPSCs, NAA15-/- iPSCs, or both revealed a total of 1209 proteins that were differentially expressed (pairwise comparison by <italic>t</italic> test) compared with WT iPSCs (Figure <xref ref-type="fig" rid="F4">4</xref>A and <xref ref-type="fig" rid="F4">4</xref>B, Figure VII and Tables VIII through X in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). Five hundred sixty-two proteins were differentially expressed in both <italic>NAA15</italic><sup>+/−</sup> and <italic>NAA15</italic><sup>−/−</sup> iPSCs compared with WT iPSCs and 505 proteins in <italic>NAA15</italic><sup>−/−</sup> iPSCs but not <italic>NAA15</italic><sup>+/−</sup> iPSCs (Figure <xref ref-type="fig" rid="F4">4</xref>B, Figure VII and Tables VIII through X in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). More than 60% of differentially expressed proteins had a NatA-target residue at position 2 of the mature protein (Table XI in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). NatA-target residues, alanine and serine, were frequently observed at position 2. Similar frequencies are seen in proteins with no expression changes (Table XI in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). Despite the large numbers of differentially expressed proteins, there were very few, if any, significant differences in mRNA levels, as assessed by RNAseq analysis (Tables III and IV in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>).</p>
                <p>Among differentially expressed proteins identified in <italic>NAA15</italic><sup>+/−</sup> iPSCs and <italic>NAA15</italic><sup>−/−</sup> iPSCs, the levels of HYPK, a component of the NatA complex that interacts with NAA15, were significantly reduced (Figure <xref ref-type="fig" rid="F1">1</xref>C).<sup><xref rid="R14" ref-type="bibr">14</xref>–<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R22" ref-type="bibr">22</xref></sup> A total of 29 out of 54 known interactors of HYPK were detected in the WT iPSCs.<sup><xref rid="R47" ref-type="bibr">47</xref></sup> Although HYPK was decreased in MS measurements, there was no enrichment of HYPK interacting proteins that were differentially expressed. Only 6 of 29 known HYPK interacting proteins were decreased in <italic>NAA15</italic>-mutant iPSCs (<italic>P</italic>=0.3; Tables IX and X in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>).</p>
                <p>To test the hypothesis that differentially expressed proteins shared a common function, the 562 proteins differentially expressed in both <italic>NAA15</italic><sup>+/−</sup> and <italic>NAA15</italic><sup>−/−</sup> iPSCs were analyzed by gene ontology analysis using clusterProfiler (implemented in R; Methods in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>).<sup><xref rid="R28" ref-type="bibr">28</xref></sup> Of the 3 gene ontology enrichment processes that were performed, we found no enrichment after Bonferroni correction for proteins with shared biological function or molecular processes; however, 41 ribosomal (-associated) proteins with altered expression levels were observed (<italic>P</italic>=5×10<sup>−6</sup>), Table XII in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>, Figure <xref ref-type="fig" rid="F4">4</xref>C). These proteins included the catalytic subunit of the NatA complex, NAA10, and ribosomal proteins of the 60S large and 40S small ribosome subunits that function in protein synthesis (Figure <xref ref-type="fig" rid="F1">1</xref>B, Table XII in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>, and Figure <xref ref-type="fig" rid="F4">4</xref>D and <xref ref-type="fig" rid="F4">4</xref>E).<sup><xref rid="R48" ref-type="bibr">48</xref>–<xref rid="R52" ref-type="bibr">52</xref></sup></p>
              </sec>
              <sec>
                <title>Ribosomal Protein Deficiency Due to NAA15 Haploinsufficiency</title>
                <p>Twenty-nine ribosomal proteins of the 84 proteins that comprise 60S or 40S ribosomal subunit<sup><xref rid="R53" ref-type="bibr">53</xref>,<xref rid="R54" ref-type="bibr">54</xref></sup> were affected in <italic>NAA15</italic><sup>+/−</sup> and <italic>NAA15</italic><sup>−/−</sup> iPSCs; eleven 60S large ribosomal proteins and 6 small ribosomal proteins were affected in both <italic>NAA15</italic><sup>+/−</sup> and <italic>NAA15</italic><sup>−/−</sup> iPSCs (Tables IX and X in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>, Figure <xref ref-type="fig" rid="F4">4</xref>D). Twelve ribosomal proteins were differentially expressed in <italic>NAA15</italic><sup>−/−</sup> iPSCs but not in <italic>NAA15</italic><sup>+/−</sup> iPSCs (Tables IX and X in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>).</p>
                <p>NAA15 facilitates binding of the NatA complex to the ribosome.<sup><xref rid="R55" ref-type="bibr">55</xref>–<xref rid="R58" ref-type="bibr">58</xref></sup>The general docking site for NatA resides at the ribosomal exit tunnel near large ribosomal unit RPL25 (L23A), a general docking platform for various factors that are transiently associated with ribosomes.<sup><xref rid="R55" ref-type="bibr">55</xref>,<xref rid="R57" ref-type="bibr">57</xref>,<xref rid="R59" ref-type="bibr">59</xref>–<xref rid="R61" ref-type="bibr">61</xref></sup> Dysregulated ribosomal proteins observed in both <italic>NAA15</italic><sup>+/−</sup> and <italic>NAA15</italic><sup>−/−</sup> iPSCs clustered near the NatA docking site (Figure <xref ref-type="fig" rid="F5">5</xref>A through <xref ref-type="fig" rid="F5">5</xref>C). Affected small ribosomal subunits (RPS18, RPS25, RPS16, RPS19, RPS20) were clustered at the head of the small ribosomal subunit<sup><xref rid="R53" ref-type="bibr">53</xref></sup> (Figure <xref ref-type="fig" rid="F5">5</xref>C). Large ribosomal units<sup><xref rid="R53" ref-type="bibr">53</xref></sup> (RPL5 [ribosomal protein L5], RPL13, RPL15, RPL19, RPL30, RPL31, RPL35, RPL23A, RPL39) with low protein levels were clustered at the exit tunnel of the ribosome near the NAA15/NatA docking site (Figure <xref ref-type="fig" rid="F5">5</xref>B).</p>
                <fig id="F5" orientation="portrait" position="float">
                  <label>Figure 5.</label>
                  <caption>
                    <p><bold>Ribosomal proteins of the 40S small and 60S large subunits affected in <italic>NAA15</italic> (N-alpha-acetyltransferase 15)-mutant iPSCs.</bold><bold>A</bold>, Graphical representation of the human 80S ribosomes with affected 40S small and 60S large subunits in both <italic>NAA15</italic><sup>−/−</sup> and <italic>NAA15</italic><sup>+/−</sup> iPSCs. Ribosomal proteins down in expression highlighted in dark blue (log2 fold change &lt;−2) and light blue (−2&lt; log2 fold change &gt;−1). NatA (N-terminal acetyltransferase) Docking site is highlighted in yellow. <bold>B</bold>, Diagram showing location of affected 60S large subunits and (<bold>C</bold>) 40S small subunits. Large ribosomal proteins are clustered and located near the NatA docking site. Small ribosomal proteins affected in their expression clustered together.</p>
                  </caption>
                  <graphic xlink:href="res-128-1156-g007"/>
                </fig>
              </sec>
              <sec>
                <title>Fetal Heart Expression and Association With CHD of Proteins Perturbed in NAA15-Haploinsufficient iPSCs</title>
                <p>Because extensive protein expression studies of human and mouse fetal heart are not available, we assessed expression of the RNAs encoding these proteins in the mouse and human fetal heart<sup><xref rid="R62" ref-type="bibr">62</xref></sup>; ≈50% of the 562 proteins are expressed in the mouse and human fetal heart (unpublished). Of these 562 proteins, 4 (DHCR7 [7-dehydrocholesterol reductase], MAP2K2 [mitogen-activated protein kinase kinase 2], NSD1 [nuclear receptor binding SET domain protein 1], and RPL5; Table XIII in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>) are encoded by genes known to cause autosomal dominant CHD (Table XIII in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). RNA encoding all 4 of these proteins are found in multiple cell types in the human fetal heart (Figure VIII in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>).</p>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>Discussion</title>
              <p>Exome sequence analyses of 4511 CHD subjects with extra-cardiac phenotypes identified 20 subjects with rare inherited or de novo variants that are predicted to perturb NAA15 (Table I and Figure I in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>, Figure <xref ref-type="fig" rid="F1">1</xref>A). Similar <italic>NAA15</italic> variants occur in patients with neurological abnormalites.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup> We explored the consequences of <italic>NAA15</italic> variants using human iPSCs by both transcriptome (RNAseq) and proteomic analyses (Figure <xref ref-type="fig" rid="F2">2</xref>; Figure II and Tables III, IV, VIII, IX, and X in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). <italic>NAA15</italic><sup>+/−</sup> cells had ≈50% of normal levels but like <italic>NAA15</italic><sup><italic>+/R276W</italic></sup> iPSCs, these differentiated into cardiomyocytes. <italic>NAA15</italic><sup>+/−</sup> iPSC-CMs displayed normal unloaded contractility, but impaired contractility when loaded (ie, working against resistance; Figure V in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>). <italic>NAA15</italic><sup>−/−</sup> iPSCs produced no NAA15 and like yeast cells lacking NAA15, grew slowly (Figure <xref ref-type="fig" rid="F2">2</xref>D).<sup><xref rid="R19" ref-type="bibr">19</xref></sup> NAA15-deficiency had minimal effect on the transcriptome but significantly altered the proteome consistent with its role in protein modification.</p>
              <p>Because NAA15 is a component of the NatA complex, we assessed the level of N-terminal protein acetylation in iPSCs carrying <italic>NAA15</italic> variants using positional proteomics. Approximately 650 proteins with N-terminal sequences that were predicted to be NatA targets could be assessed. Only 32 and 9 proteins had altered Nt-acetylation in NAA15 null and haploinsufficient cells, respectively. By contrast, levels of 562 proteins were altered in both NAA15-null and NAA15-haploinsufficient cells suggesting a possible role for NAA15 and NatA in translation efficiency and protein stability in addition to Nt-acetylation. If NAA15 was the only available ribosome anchor for NAA10 and the NatA complex in human cells as it is in yeast cells,<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R55" ref-type="bibr">55</xref>,<xref rid="R58" ref-type="bibr">58</xref></sup> NAA15 null cells should present with a complete lack of Nt-acetylation of all NatA substrates. The explanation for the partial effect observed may be due to the presence of the NAA15 paralogue NAA16 in human cells; however, the low expression of NAA16 in iPSCs suggests the need for additional studies to measure whether the paralogue to NAA15 had any effect on N-terminal acetylation. It has been reported that NAA16-NAA10 complexes may perform NatA-type Nt-acetylation in human cells and partially act as a backup system for the NAA15-NAA10 NatA complex.<sup><xref rid="R63" ref-type="bibr">63</xref></sup></p>
              <p>The levels of 18 of the 81 identified ribosomal proteins were altered in NAA15-haploinsufficent cells. NAA15 anchors the NatA complex to the ribosomal large subunit via RPL25 (L23A).<sup><xref rid="R55" ref-type="bibr">55</xref>–<xref rid="R58" ref-type="bibr">58</xref>,<xref rid="R64" ref-type="bibr">64</xref></sup> Consistent with this model, some of these affected proteins clustered near the NAA15/NatA docking site. Presumably, NAA15 binding to one or more of these proteins<sup><xref rid="R56" ref-type="bibr">56</xref></sup> protects them from subsequent degradation either during ribosome assembly or subsequent ribosomal activity. Previous studies have demonstrated that ribosomal subunit deficiency leads to a variety of pathological states.<sup><xref rid="R48" ref-type="bibr">48</xref>,<xref rid="R50" ref-type="bibr">50</xref>,<xref rid="R51" ref-type="bibr">51</xref>,<xref rid="R65" ref-type="bibr">65</xref></sup> Damaging human variants in ribosomal subunits RPS19, RPL5,<sup><xref rid="R4" ref-type="bibr">4</xref></sup> and RPL35A have been identified in patients with CHD<sup><xref rid="R4" ref-type="bibr">4</xref></sup> (PCGC consortium data not shown) and also contribute to Diamond-Blackfan anemia,<sup><xref rid="R50" ref-type="bibr">50</xref>,<xref rid="R66" ref-type="bibr">66</xref>,<xref rid="R67" ref-type="bibr">67</xref></sup> a disorder that is accompanied by CHD in 30% of patients.<sup><xref rid="R68" ref-type="bibr">68</xref></sup></p>
              <p>Among differentially expressed proteins in NAA15 haploinsufficient cells, 4 (DHCR7, MAP2K2, NSD1, and RPL5) are encoded by known CHD genes (Table XIII and Figure VIII in the <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">Data Supplement</ext-link>) and are most likely responsible for NAA15-haploinsufficient mediated CHD.<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R69" ref-type="bibr">69</xref>–<xref rid="R71" ref-type="bibr">71</xref></sup> As the precise mechanisms by which each haploinsufficiency of each of these genes is defined, we anticipate the mechanism(s) will be shared by NAA15 haploinsufficient patients.</p>
              <p>Exome analyses of CHD probands also identified 16 <italic>NAA15</italic> missense variants, including R276W, a variant of uncertain significance. iPSCs carrying the <italic>NAA15</italic> R276W variant had eight proteins with altered Nt-acetylation, of which 4 had altered Nt-acetylation in NAA15-haploinsufficient cells. These data suggest that the R276W variant likely impairs NAA15 function, and consequently NatA function, and like heterozygous LoF variants contributes to CHD. Future studies of protein levels in genetically engineered iPSCs carrying other <italic>NAA15</italic> variants found in CHD probands, will help identify those variants contributing to cardiac abnormalities and those variants that are likely benign.</p>
              <p>In this study, we use genetically engineered iPSC models to recapitulate <italic>NAA15</italic> LoF and missense variants discovered in CHD patients. We observe that variants in <italic>NAA15</italic> causing <italic>NAA15</italic> haploinsufficiency or deficiency result in either a reduction or complete depletion of NAA15 and NatA protein levels. We find that aberrant protein expression of NAA15 alters Nt-acetylation of a small number of proteins. Most importantly, a reduction of the NAA15 protein interrupts its interaction with the ribosome. The failed interaction causes ribosomal deficiency and mis-expression of a large number of proteins most likely involved in heart development. Protein expression changes are possibly due to obstructed ribosomal machinery and defects in protein synthesis. One or more proteins affected in both <italic>NAA15</italic>-mutant iPSCs have been documented as a cause of congenital heart defects and are likely candidates required for normal cardiac developmental processes.</p>
            </sec>
            <sec>
              <title>Acknowledgments</title>
              <p>We would like to thank Paula Montero Llopis of the MicRoN (Microscopy Resources On the North Quad) core for her support and assistance, specifically for collecting images in Figure <xref ref-type="fig" rid="F2">2</xref>. We appreciate the study participants and their families, without whom this work would not have been possible.</p>
            </sec>
            <sec>
              <title>Sources of Funding</title>
              <p>We gratefully acknowledge the National Heart, Lung, and Blood Institute Pediatrics Cardiac Genomics Consortium (PCGC) and Cardiovascular Development Consortium (CVDC) investigators (B.D. Gelb, W.K. Chung, E. Goldmuntz, G.A. Porter, R.P. Lifton, M. Brueckner, H.J. Yost, B.G. Bruneau, C.E. Seidman, J.G. Seidman) for their support and expertise in cardiovascular development. Funding support for this study was provided by grants to the PCGC and CVDC by the US National Heart Lung and Blood Institute (UM1 HL098123 [B.D. Gelb], U01 HL098153 [EG], UM1HL098179 [B.G. Bruneau], R01 HL151257 [C.E. Seidman], 1UM1HL098166 [J.G. Seidman]), SFARI and the JPB Foundation (W.K. Chung), Harvard Medical School Diversity and Inclusion Dean’s Postdoctoral Fellowship (T. Ward), Stanley J. Sarnoff Cardiovascular Research Foundation (W. Tai), HHMI Medical Research Fellowship (M.Y. Jang), FAPESP number 19/11921-1 and 18/13706-0 (G. Venturini), K. Zhang acknowledges fellowship support from the American Heart Association, award number 17PRE33660967, John S. Ladue Memorial Fellowship at Harvard Medical School (Y. Kim), S. Varland and T.Arnesen were funded by the Research Council of Norway through a FRIPRO mobility grant 261981, which is cofounded by the European Union’s Seventh Framework Programme under Marie Curie grant agreement no 608695, the Research Council of Norway (project 249843), the Norwegian Health Authorities of Western Norway (project F-12540), and the Norwegian Cancer Society. Funding was supported by the Engineering Research Centers Program of the National Science Foundation, no.EEC-1647837(C.S. Chen). K. Gevaert acknowledges support from The Research Foundation—Flanders (FWO), project number G008018N. Funding was supported by the Howard Hughes Medical Institute (C.E. Seidman), and Fondation Leducq 16 CVD 03 (J.G. Seidman).</p>
            </sec>
            <sec sec-type="COI-Statement">
              <title>Disclosures</title>
              <p>None.</p>
            </sec>
            <sec>
              <title>Supplemental Materials</title>
              <p>Expanded Online Materials and Methods</p>
              <p>Online Figures I–VIII</p>
              <p>Online Movies I–VIII</p>
              <p>Data Set of Online Tables I–XIII</p>
              <p>References 72–76</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material content-type="local-data" id="SD1">
                <media id="s1" content-type="movie" xlink:href="res-128-1156-s001.mov" mimetype="video" mime-subtype="mov" orientation="portrait" position="anchor"/>
                <media id="s2" content-type="movie" xlink:href="res-128-1156-s002.mov" mimetype="video" mime-subtype="mov" orientation="portrait" position="anchor"/>
                <media id="s3" content-type="movie" xlink:href="res-128-1156-s003.mp4" mimetype="video" mime-subtype="mp4" orientation="portrait" position="anchor"/>
                <media id="s4" content-type="movie" xlink:href="res-128-1156-s004.mp4" mimetype="video" mime-subtype="mp4" orientation="portrait" position="anchor"/>
                <media id="s5" content-type="movie" xlink:href="res-128-1156-s005.mp4" mimetype="video" mime-subtype="mp4" orientation="portrait" position="anchor"/>
                <media id="s6" content-type="movie" xlink:href="res-128-1156-s006.mp4" mimetype="video" mime-subtype="mp4" orientation="portrait" position="anchor"/>
                <media id="s7" content-type="movie" xlink:href="res-128-1156-s007.mp4" mimetype="video" mime-subtype="mp4" orientation="portrait" position="anchor"/>
                <media id="s8" content-type="movie" xlink:href="res-128-1156-s008.mp4" mimetype="video" mime-subtype="mp4" orientation="portrait" position="anchor"/>
                <media id="s9" content-type="document" xlink:href="res-128-1156-s009.pdf" mimetype="application" mime-subtype="pdf" orientation="portrait" position="anchor"/>
                <media id="s10" content-type="image" xlink:href="res-128-1156-s010.jpg" mimetype="image" mime-subtype="jpg" orientation="portrait" position="anchor"/>
                <media id="s11" content-type="document" xlink:href="res-128-1156-s011.pdf" mimetype="application" mime-subtype="pdf" orientation="portrait" position="anchor"/>
                <media id="s12" content-type="document" xlink:href="res-128-1156-s012.xlsx" mimetype="application" mime-subtype="xlsx" orientation="portrait" position="anchor"/>
                <media id="s13" content-type="document" xlink:href="res-128-1156-s013.pdf" mimetype="application" mime-subtype="pdf" orientation="portrait" position="anchor"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="abbr">
                <p>
                  <def-list>
                    <title>Nonstandard Abbreviations and Acronyms</title>
                    <def-item>
                      <term>CHD</term>
                      <def>
                        <p>congenital heart disease</p>
                      </def>
                    </def-item>
                    <def-item>
                      <term>GFP</term>
                      <def>
                        <p>green fluorescent protein</p>
                      </def>
                    </def-item>
                    <def-item>
                      <term>iPSC</term>
                      <def>
                        <p>induced pluripotent stem cells</p>
                      </def>
                    </def-item>
                    <def-item>
                      <term>iPSC-CMs</term>
                      <def>
                        <p>induced pluripotent stem cell-derived cardiomyocytes</p>
                      </def>
                    </def-item>
                    <def-item>
                      <term>LoF</term>
                      <def>
                        <p>loss of function</p>
                      </def>
                    </def-item>
                    <def-item>
                      <term>NAT</term>
                      <def>
                        <p>N-terminal acetyltransferase</p>
                      </def>
                    </def-item>
                    <def-item>
                      <term>Nt</term>
                      <def>
                        <p>N-terminal</p>
                      </def>
                    </def-item>
                  </def-list>
                </p>
              </fn>
            </fn-group>
            <fn-group>
              <fn fn-type="equal" id="fn01">
                <label>*</label>
                <p>K. Gevaert, C. Seidman, and J.G. Seidman contributed equally.</p>
              </fn>
              <fn fn-type="supplementary-material" id="fn02">
                <p>The Data Supplement is available with this article at <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966">https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966</ext-link>.</p>
              </fn>
              <fn fn-type="financial-disclosure" id="fn03">
                <p>For Sources of Funding and Disclosures, see page 1167.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Linde</surname><given-names>D</given-names></name><name><surname>Konings</surname><given-names>EE</given-names></name><name><surname>Slager</surname><given-names>MA</given-names></name><name><surname>Witsenburg</surname><given-names>M</given-names></name><name><surname>Helbing</surname><given-names>WA</given-names></name><name><surname>Takkenberg</surname><given-names>JJ</given-names></name><name><surname>Roos-Hesselink</surname><given-names>JW</given-names></name></person-group>. <article-title>Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis.</article-title><source>J Am Coll Cardiol</source>. <year>2011</year>;<volume>58</volume>:<fpage>2241</fpage>–<lpage>2247</lpage>. <comment>doi: 10.1016/j.jacc.2011.08.025</comment><pub-id pub-id-type="pmid">22078432</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homsy</surname><given-names>J</given-names></name><name><surname>Zaidi</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Ware</surname><given-names>JS</given-names></name><name><surname>Samocha</surname><given-names>KE</given-names></name><name><surname>Karczewski</surname><given-names>KJ</given-names></name><name><surname>DePalma</surname><given-names>SR</given-names></name><name><surname>McKean</surname><given-names>D</given-names></name><name><surname>Wakimoto</surname><given-names>H</given-names></name><name><surname>Gorham</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies.</article-title><source>Science</source>. <year>2015</year>;<volume>350</volume>:<fpage>1262</fpage>–<lpage>1266</lpage>. <comment>doi: 10.1126/science.aac9396</comment><pub-id pub-id-type="pmid">26785492</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaidi</surname><given-names>S</given-names></name><name><surname>Choi</surname><given-names>M</given-names></name><name><surname>Wakimoto</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Overton</surname><given-names>JD</given-names></name><name><surname>Romano-Adesman</surname><given-names>A</given-names></name><name><surname>Bjornson</surname><given-names>RD</given-names></name><name><surname>Breitbart</surname><given-names>RE</given-names></name><name><surname>Brown</surname><given-names>KK</given-names></name><etal/></person-group>. <article-title>De novo mutations in histone-modifying genes in congenital heart disease.</article-title><source>Nature</source>. <year>2013</year>;<volume>498</volume>:<fpage>220</fpage>–<lpage>223</lpage>. <comment>doi: 10.1038/nature12141</comment><pub-id pub-id-type="pmid">23665959</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>SC</given-names></name><name><surname>Homsy</surname><given-names>J</given-names></name><name><surname>Zaidi</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Morton</surname><given-names>S</given-names></name><name><surname>DePalma</surname><given-names>SR</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Qi</surname><given-names>H</given-names></name><name><surname>Chang</surname><given-names>W</given-names></name><name><surname>Sierant</surname><given-names>MC</given-names></name><etal/></person-group>. <article-title>Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands.</article-title><source>Nat Genet</source>. <year>2017</year>;<volume>49</volume>:<fpage>1593</fpage>–<lpage>1601</lpage>. <comment>doi: 10.1038/ng.3970</comment><pub-id pub-id-type="pmid">28991257</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>H</given-names></name><name><surname>Dharmadhikari</surname><given-names>AV</given-names></name><name><surname>Varland</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>N</given-names></name><name><surname>Domingo</surname><given-names>D</given-names></name><name><surname>Kleyner</surname><given-names>R</given-names></name><name><surname>Rope</surname><given-names>AF</given-names></name><name><surname>Yoon</surname><given-names>M</given-names></name><name><surname>Stray-Pedersen</surname><given-names>A</given-names></name><name><surname>Posey</surname><given-names>JE</given-names></name><etal/></person-group>. <article-title>Truncating variants in NAA15 are associated with variable levels of intellectual disability, autism spectrum disorder, and congenital anomalies.</article-title><source>Am J Hum Genet</source>. <year>2018</year>;<volume>102</volume>:<fpage>985</fpage>–<lpage>994</lpage>. <comment>doi: 10.1016/j.ajhg.2018.03.004</comment><pub-id pub-id-type="pmid">29656860</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Long</surname><given-names>M</given-names></name><name><surname>Coe</surname><given-names>BP</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Xun</surname><given-names>G</given-names></name><name><surname>Ou</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Duan</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Inherited and multiple de novo mutations in autism/developmental delay risk genes suggest a multifactorial model.</article-title><source>Mol Autism</source>. <year>2018</year>;<volume>9</volume>:<fpage>64</fpage>. <comment>doi: 10.1186/s13229-018-0247-z</comment><pub-id pub-id-type="pmid">30564305</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>JJ</given-names></name><name><surname>Halvardson</surname><given-names>J</given-names></name><name><surname>Zander</surname><given-names>CS</given-names></name><name><surname>Zaghlool</surname><given-names>A</given-names></name><name><surname>Georgii-Hemming</surname><given-names>P</given-names></name><name><surname>Månsson</surname><given-names>E</given-names></name><name><surname>Brandberg</surname><given-names>G</given-names></name><name><surname>Sävmarker</surname><given-names>HE</given-names></name><name><surname>Frykholm</surname><given-names>C</given-names></name><name><surname>Kuchinskaya</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Exome sequencing reveals NAA15 and PUF60 as candidate genes associated with intellectual disability.</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source>. <year>2018</year>;<volume>177</volume>:<fpage>10</fpage>–<lpage>20</lpage>. <comment>doi: 10.1002/ajmg.b.32574</comment><pub-id pub-id-type="pmid">28990276</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnesen</surname><given-names>T</given-names></name><name><surname>Van Damme</surname><given-names>P</given-names></name><name><surname>Polevoda</surname><given-names>B</given-names></name><name><surname>Helsens</surname><given-names>K</given-names></name><name><surname>Evjenth</surname><given-names>R</given-names></name><name><surname>Colaert</surname><given-names>N</given-names></name><name><surname>Varhaug</surname><given-names>JE</given-names></name><name><surname>Vandekerckhove</surname><given-names>J</given-names></name><name><surname>Lillehaug</surname><given-names>JR</given-names></name><name><surname>Sherman</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Proteomics analyses reveal the evolutionary conservation and divergence of N-terminal acetyltransferases from yeast and humans.</article-title><source>Proc Natl Acad Sci U S A</source>. <year>2009</year>;<volume>106</volume>:<fpage>8157</fpage>–<lpage>8162</lpage>. <comment>doi: 10.1073/pnas.0901931106</comment><pub-id pub-id-type="pmid">19420222</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drazic</surname><given-names>A</given-names></name><name><surname>Myklebust</surname><given-names>LM</given-names></name><name><surname>Ree</surname><given-names>R</given-names></name><name><surname>Arnesen</surname><given-names>T</given-names></name></person-group>. <article-title>The world of protein acetylation.</article-title><source>Biochim Biophys Acta</source>. <year>2016</year>;<volume>1864</volume>:<fpage>1372</fpage>–<lpage>1401</lpage>. <comment>doi: 10.1016/j.bbapap.2016.06.007</comment><pub-id pub-id-type="pmid">27296530</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aksnes</surname><given-names>H</given-names></name><name><surname>Drazic</surname><given-names>A</given-names></name><name><surname>Marie</surname><given-names>M</given-names></name><name><surname>Arnesen</surname><given-names>T</given-names></name></person-group>. <article-title>First things first: vital protein marks by N-terminal acetyltransferases.</article-title><source>Trends Biochem Sci</source>. <year>2016</year>;<volume>41</volume>:<fpage>746</fpage>–<lpage>760</lpage>. <comment>doi: 10.1016/j.tibs.2016.07.005</comment><pub-id pub-id-type="pmid">27498224</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aksnes</surname><given-names>H</given-names></name><name><surname>Ree</surname><given-names>R</given-names></name><name><surname>Arnesen</surname><given-names>T</given-names></name></person-group>. <article-title>Co-translational, post-translational, and non-catalytic roles of N-terminal acetyltransferases.</article-title><source>Mol Cell</source>. <year>2019</year>;<volume>73</volume>:<fpage>1097</fpage>–<lpage>1114</lpage>. <comment>doi: 10.1016/j.molcel.2019.02.007</comment><pub-id pub-id-type="pmid">30878283</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frottin</surname><given-names>F</given-names></name><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Peynot</surname><given-names>P</given-names></name><name><surname>Mitra</surname><given-names>S</given-names></name><name><surname>Holz</surname><given-names>RC</given-names></name><name><surname>Giglione</surname><given-names>C</given-names></name><name><surname>Meinnel</surname><given-names>T</given-names></name></person-group>. <article-title>The proteomics of N-terminal methionine cleavage.</article-title><source>Mol Cell Proteomics</source>. <year>2006</year>;<volume>5</volume>:<fpage>2336</fpage>–<lpage>2349</lpage>. <comment>doi: 10.1074/mcp.M600225-MCP200</comment><pub-id pub-id-type="pmid">16963780</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnold</surname><given-names>RJ</given-names></name><name><surname>Polevoda</surname><given-names>B</given-names></name><name><surname>Reilly</surname><given-names>JP</given-names></name><name><surname>Sherman</surname><given-names>F</given-names></name></person-group>. <article-title>The action of N-terminal acetyltransferases on yeast ribosomal proteins.</article-title><source>J Biol Chem</source>. <year>1999</year>;<volume>274</volume>:<fpage>37035</fpage>–<lpage>37040</lpage>. <comment>doi: 10.1074/jbc.274.52.37035</comment><pub-id pub-id-type="pmid">10601260</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhury</surname><given-names>KR</given-names></name><name><surname>Raychaudhuri</surname><given-names>S</given-names></name><name><surname>Bhattacharyya</surname><given-names>NP</given-names></name></person-group>. <article-title>Identification of HYPK-interacting proteins reveals involvement of HYPK in regulating cell growth, cell cycle, unfolded protein response and cell death.</article-title><source>PLoS One</source>. <year>2012</year>;<volume>7</volume>:<fpage>e51415</fpage>. <comment>doi: 10.1371/journal.pone.0051415</comment><pub-id pub-id-type="pmid">23272104</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottlieb</surname><given-names>L</given-names></name><name><surname>Marmorstein</surname><given-names>R</given-names></name></person-group>. <article-title>Structure of human NatA and its regulation by the huntingtin interacting protein HYPK.</article-title><source>Structure</source>. <year>2018</year>;<volume>26</volume>:<fpage>925</fpage>–<lpage>935.e8</lpage>. <comment>doi: 10.1016/j.str.2018.04.003</comment><pub-id pub-id-type="pmid">29754825</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raychaudhuri</surname><given-names>S</given-names></name><name><surname>Sinha</surname><given-names>M</given-names></name><name><surname>Mukhopadhyay</surname><given-names>D</given-names></name><name><surname>Bhattacharyya</surname><given-names>NP</given-names></name></person-group>. <article-title>HYPK, a Huntingtin interacting protein, reduces aggregates and apoptosis induced by N-terminal Huntingtin with 40 glutamines in Neuro2a cells and exhibits chaperone-like activity.</article-title><source>Hum Mol Genet</source>. <year>2008</year>;<volume>17</volume>:<fpage>240</fpage>–<lpage>255</lpage>. <comment>doi: 10.1093/hmg/ddm301</comment><pub-id pub-id-type="pmid">17947297</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weyer</surname><given-names>FA</given-names></name><name><surname>Gumiero</surname><given-names>A</given-names></name><name><surname>Lapouge</surname><given-names>K</given-names></name><name><surname>Bange</surname><given-names>G</given-names></name><name><surname>Kopp</surname><given-names>J</given-names></name><name><surname>Sinning</surname><given-names>I</given-names></name></person-group>. <article-title>Structural basis of HypK regulating N-terminal acetylation by the NatA complex.</article-title><source>Nat Commun</source>. <year>2017</year>;<volume>8</volume>:<fpage>15726</fpage>. <comment>doi: 10.1038/ncomms15726</comment><pub-id pub-id-type="pmid">28585574</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Magin</surname><given-names>RS</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Pan</surname><given-names>B</given-names></name><name><surname>Petersson</surname><given-names>EJ</given-names></name><name><surname>Marmorstein</surname><given-names>R</given-names></name></person-group>. <article-title>Structure and mechanism of acetylation by the N-terminal dual enzyme NatA/Naa50 complex.</article-title><source>Structure</source>. <year>2019</year>;<volume>27</volume>:<fpage>1057</fpage>–<lpage>1070.e4</lpage>. <comment>doi: 10.1016/j.str.2019.04.014</comment><pub-id pub-id-type="pmid">31155310</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullen</surname><given-names>JR</given-names></name><name><surname>Kayne</surname><given-names>PS</given-names></name><name><surname>Moerschell</surname><given-names>RP</given-names></name><name><surname>Tsunasawa</surname><given-names>S</given-names></name><name><surname>Gribskov</surname><given-names>M</given-names></name><name><surname>Colavito-Shepanski</surname><given-names>M</given-names></name><name><surname>Grunstein</surname><given-names>M</given-names></name><name><surname>Sherman</surname><given-names>F</given-names></name><name><surname>Sternglanz</surname><given-names>R</given-names></name></person-group>. <article-title>Identification and characterization of genes and mutants for an N-terminal acetyltransferase from yeast.</article-title><source>EMBO J</source>. <year>1989</year>;<volume>8</volume>:<fpage>2067</fpage>–<lpage>2075</lpage><pub-id pub-id-type="pmid">2551674</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnesen</surname><given-names>T</given-names></name><name><surname>Anderson</surname><given-names>D</given-names></name><name><surname>Baldersheim</surname><given-names>C</given-names></name><name><surname>Lanotte</surname><given-names>M</given-names></name><name><surname>Varhaug</surname><given-names>JE</given-names></name><name><surname>Lillehaug</surname><given-names>JR</given-names></name></person-group>. <article-title>Identification and characterization of the human ARD1–NATH protein acetyltransferase complex</article-title><year>2005</year>;<volume>386</volume>:<fpage>433</fpage>–<lpage>443</lpage></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liszczak</surname><given-names>G</given-names></name><name><surname>Goldberg</surname><given-names>JM</given-names></name><name><surname>Foyn</surname><given-names>H</given-names></name><name><surname>Petersson</surname><given-names>EJ</given-names></name><name><surname>Arnesen</surname><given-names>T</given-names></name><name><surname>Marmorstein</surname><given-names>R</given-names></name></person-group>. <article-title>Molecular basis for N-terminal acetylation by the heterodimeric NatA complex.</article-title><source>Nat Struct Mol Biol</source>. <year>2013</year>;<volume>20</volume>:<fpage>1098</fpage>–<lpage>1105</lpage>. <comment>doi: 10.1038/nsmb.2636</comment><pub-id pub-id-type="pmid">23912279</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnesen</surname><given-names>T</given-names></name><name><surname>Starheim</surname><given-names>KK</given-names></name><name><surname>Van Damme</surname><given-names>P</given-names></name><name><surname>Evjenth</surname><given-names>R</given-names></name><name><surname>Dinh</surname><given-names>H</given-names></name><name><surname>Betts</surname><given-names>MJ</given-names></name><name><surname>Ryningen</surname><given-names>A</given-names></name><name><surname>Vandekerckhove</surname><given-names>J</given-names></name><name><surname>Gevaert</surname><given-names>K</given-names></name><name><surname>Anderson</surname><given-names>D</given-names></name></person-group>. <article-title>The chaperone-like protein HYPK acts together with NatA in cotranslational N-terminal acetylation and prevention of Huntingtin aggregation.</article-title><source>Mol Cell Biol</source>. <year>2010</year>;<volume>30</volume>:<fpage>1898</fpage>–<lpage>1909</lpage>. <comment>doi: 10.1128/MCB.01199-09</comment><pub-id pub-id-type="pmid">20154145</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myklebust</surname><given-names>LM</given-names></name><name><surname>Van Damme</surname><given-names>P</given-names></name><name><surname>Støve</surname><given-names>SI</given-names></name><name><surname>Dörfel</surname><given-names>MJ</given-names></name><name><surname>Abboud</surname><given-names>A</given-names></name><name><surname>Kalvik</surname><given-names>TV</given-names></name><name><surname>Grauffel</surname><given-names>C</given-names></name><name><surname>Jonckheere</surname><given-names>V</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Swensen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Biochemical and cellular analysis of Ogden syndrome reveals downstream Nt-acetylation defects.</article-title><source>Hum Mol Genet</source>. <year>2015</year>;<volume>24</volume>:<fpage>1956</fpage>–<lpage>1976</lpage>. <comment>doi: 10.1093/hmg/ddu611</comment><pub-id pub-id-type="pmid">25489052</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fluge</surname><given-names>Ø</given-names></name><name><surname>Bruland</surname><given-names>O</given-names></name><name><surname>Akslen</surname><given-names>LA</given-names></name><name><surname>Varhaug</surname><given-names>JE</given-names></name><name><surname>Lillehaug</surname><given-names>JR</given-names></name></person-group>. <article-title>NATH, a novel gene overexpressed in papillary thyroid carcinomas.</article-title><source>Oncogene</source>. <year>2002</year>;<volume>21</volume>:<fpage>5056</fpage>–<lpage>5068</lpage>. <comment>doi: 10.1038/sj.onc.1205687</comment><pub-id pub-id-type="pmid">12140756</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelb</surname><given-names>B</given-names></name><name><surname>Brueckner</surname><given-names>M</given-names></name><name><surname>Chung</surname><given-names>W</given-names></name><name><surname>Goldmuntz</surname><given-names>E</given-names></name><name><surname>Kaltman</surname><given-names>J</given-names></name><name><surname>Kaski</surname><given-names>JP</given-names></name><name><surname>Kim</surname><given-names>R</given-names></name><name><surname>Kline</surname><given-names>J</given-names></name><name><surname>Mercer-Rosa</surname><given-names>L</given-names></name><name><surname>Porter</surname><given-names>G</given-names></name><etal/></person-group>; <collab>Pediatric Cardiac Genomics Consortium</collab>. <article-title>The congenital heart disease genetic network study.</article-title><source>Circulation Research</source>. <year>2013</year>;<volume>112</volume>:<fpage>698</fpage>–<lpage>706</lpage><pub-id pub-id-type="pmid">23410879</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohye</surname><given-names>RG</given-names></name><name><surname>Sleeper</surname><given-names>LA</given-names></name><name><surname>Mahony</surname><given-names>L</given-names></name><name><surname>Newburger</surname><given-names>JW</given-names></name><name><surname>Pearson</surname><given-names>GD</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Goldberg</surname><given-names>CS</given-names></name><name><surname>Tabbutt</surname><given-names>S</given-names></name><name><surname>Frommelt</surname><given-names>PC</given-names></name><name><surname>Ghanayem</surname><given-names>NS</given-names></name><etal/></person-group>; <collab>Pediatric Heart Network Investigators</collab>. <article-title>Comparison of shunt types in the Norwood procedure for single-ventricle lesions.</article-title><source>N Engl J Med</source>. <year>2010</year>;<volume>362</volume>:<fpage>1980</fpage>–<lpage>1992</lpage>. <comment>doi: 10.1056/NEJMoa0912461</comment><pub-id pub-id-type="pmid">20505177</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Toepfer</surname><given-names>CN</given-names></name><name><surname>Ward</surname><given-names>T</given-names></name><name><surname>Wasson</surname><given-names>L</given-names></name><name><surname>Agarwal</surname><given-names>R</given-names></name><name><surname>Conner</surname><given-names>DA</given-names></name><name><surname>Hu</surname><given-names>JH</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name></person-group>. <article-title>CRISPR/Cas9-mediated fluorescent tagging of endogenous proteins in human pluripotent stem cells.</article-title><source>Current protocols in human genetics</source>. <year>2018</year>;<volume>96</volume>:<fpage>21 11 1-21 11 20</fpage></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>LG</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>QY</given-names></name></person-group>. <article-title>clusterProfiler: an R package for comparing biological themes among gene clusters.</article-title><source>OMICS</source>. <year>2012</year>;<volume>16</volume>:<fpage>284</fpage>–<lpage>287</lpage>. <comment>doi: 10.1089/omi.2011.0118</comment><pub-id pub-id-type="pmid">22455463</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tusher</surname><given-names>VG</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Chu</surname><given-names>G</given-names></name></person-group>. <article-title>Significance analysis of microarrays applied to the ionizing radiation response.</article-title><source>Proc Natl Acad Sci USA</source>. <year>2001</year>;<volume>98</volume>:<fpage>5116</fpage>–<lpage>5121</lpage>. <comment>doi: 10.1073/pnas.091062498</comment><pub-id pub-id-type="pmid">11309499</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lian</surname><given-names>X</given-names></name><name><surname>Hsiao</surname><given-names>C</given-names></name><name><surname>Wilson</surname><given-names>G</given-names></name><name><surname>Zhu</surname><given-names>K</given-names></name><name><surname>Hazeltine</surname><given-names>LB</given-names></name><name><surname>Azarin</surname><given-names>SM</given-names></name><name><surname>Raval</surname><given-names>KK</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Kamp</surname><given-names>TJ</given-names></name><name><surname>Palecek</surname><given-names>SP</given-names></name></person-group>. <article-title>Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling.</article-title><source>Proc Natl Acad Sci USA</source>. <year>2012</year>;<volume>109</volume>:<fpage>E1848</fpage>–<lpage>E1857</lpage>. <comment>doi: 10.1073/pnas.1200250109</comment><pub-id pub-id-type="pmid">22645348</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lian</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Azarin</surname><given-names>SM</given-names></name><name><surname>Zhu</surname><given-names>K</given-names></name><name><surname>Hazeltine</surname><given-names>LB</given-names></name><name><surname>Bao</surname><given-names>X</given-names></name><name><surname>Hsiao</surname><given-names>C</given-names></name><name><surname>Kamp</surname><given-names>TJ</given-names></name><name><surname>Palecek</surname><given-names>SP</given-names></name></person-group>. <article-title>Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions.</article-title><source>Nat Protoc</source>. <year>2013</year>;<volume>8</volume>:<fpage>162</fpage>–<lpage>175</lpage>. <comment>doi: 10.1038/nprot.2012.150</comment><pub-id pub-id-type="pmid">23257984</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnesen</surname><given-names>T</given-names></name><name><surname>Gromyko</surname><given-names>D</given-names></name><name><surname>Pendino</surname><given-names>F</given-names></name><name><surname>Ryningen</surname><given-names>A</given-names></name><name><surname>Varhaug</surname><given-names>JE</given-names></name><name><surname>Lillehaug</surname><given-names>JR</given-names></name></person-group>. <article-title>Induction of apoptosis in human cells by RNAi-mediated knockdown of hARD1 and NATH, components of the protein N-alpha-acetyltransferase complex.</article-title><source>Oncogene</source>. <year>2006</year>;<volume>25</volume>:<fpage>4350</fpage>–<lpage>4360</lpage>. <comment>doi: 10.1038/sj.onc.1209469</comment><pub-id pub-id-type="pmid">16518407</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gromyko</surname><given-names>D</given-names></name><name><surname>Arnesen</surname><given-names>T</given-names></name><name><surname>Ryningen</surname><given-names>A</given-names></name><name><surname>Varhaug</surname><given-names>JE</given-names></name><name><surname>Lillehaug</surname><given-names>JR</given-names></name></person-group>. <article-title>Depletion of the human Nα-terminal acetyltransferase A induces p53-dependent apoptosis and p53-independent growth inhibition.</article-title><source>Int J Cancer</source>. <year>2010</year>;<volume>127</volume>:<fpage>2777</fpage>–<lpage>2789</lpage>. <comment>doi: 10.1002/ijc.25275</comment><pub-id pub-id-type="pmid">21351257</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalvik</surname><given-names>TV</given-names></name><name><surname>Arnesen</surname><given-names>T</given-names></name></person-group>. <article-title>Protein N-terminal acetyltransferases in cancer.</article-title><source>Oncogene</source>. <year>2013</year>;<volume>32</volume>:<fpage>269</fpage>–<lpage>276</lpage>. <comment>doi: 10.1038/onc.2012.82</comment><pub-id pub-id-type="pmid">22391571</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <label>35.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toepfer</surname><given-names>CN</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Cicconet</surname><given-names>M</given-names></name><name><surname>Garfinkel</surname><given-names>AC</given-names></name><name><surname>Mücke</surname><given-names>M</given-names></name><name><surname>Neyazi</surname><given-names>M</given-names></name><name><surname>Willcox</surname><given-names>JAL</given-names></name><name><surname>Agarwal</surname><given-names>R</given-names></name><name><surname>Schmid</surname><given-names>M</given-names></name><name><surname>Rao</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>SarcTrack.</article-title><source>Circ Res</source>. <year>2019</year>;<volume>124</volume>:<fpage>1172</fpage>–<lpage>1183</lpage>. <comment>doi: 10.1161/CIRCRESAHA.118.314505</comment><pub-id pub-id-type="pmid">30700234</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <label>36.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinson</surname><given-names>JT</given-names></name><name><surname>Chopra</surname><given-names>A</given-names></name><name><surname>Nafissi</surname><given-names>N</given-names></name><name><surname>Polacheck</surname><given-names>WJ</given-names></name><name><surname>Benson</surname><given-names>CC</given-names></name><name><surname>Swist</surname><given-names>S</given-names></name><name><surname>Gorham</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Schafer</surname><given-names>S</given-names></name><name><surname>Sheng</surname><given-names>CC</given-names></name><etal/></person-group>. <article-title>HEART DISEASE. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy.</article-title><source>Science</source>. <year>2015</year>;<volume>349</volume>:<fpage>982</fpage>–<lpage>986</lpage>. <comment>doi: 10.1126/science.aaa5458</comment><pub-id pub-id-type="pmid">26315439</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <label>37.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legant</surname><given-names>WR</given-names></name><name><surname>Pathak</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>MT</given-names></name><name><surname>Deshpande</surname><given-names>VS</given-names></name><name><surname>McMeeking</surname><given-names>RM</given-names></name><name><surname>Chen</surname><given-names>CS</given-names></name></person-group>. <article-title>Microfabricated tissue gauges to measure and manipulate forces from 3D microtissues.</article-title><source>Proc Natl Acad Sci USA</source>. <year>2009</year>;<volume>106</volume>:<fpage>10097</fpage>–<lpage>10102</lpage>. <comment>doi: 10.1073/pnas.0900174106</comment><pub-id pub-id-type="pmid">19541627</pub-id></mixed-citation>
              </ref>
              <ref id="R38">
                <label>38.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gevaert</surname><given-names>K</given-names></name><name><surname>Goethals</surname><given-names>M</given-names></name><name><surname>Martens</surname><given-names>L</given-names></name><name><surname>Van Damme</surname><given-names>J</given-names></name><name><surname>Staes</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>GR</given-names></name><name><surname>Vandekerckhove</surname><given-names>J</given-names></name></person-group>. <article-title>Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides.</article-title><source>Nat Biotechnol</source>. <year>2003</year>;<volume>21</volume>:<fpage>566</fpage>–<lpage>569</lpage>. <comment>doi: 10.1038/nbt810</comment><pub-id pub-id-type="pmid">12665801</pub-id></mixed-citation>
              </ref>
              <ref id="R39">
                <label>39.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staes</surname><given-names>A</given-names></name><name><surname>Impens</surname><given-names>F</given-names></name><name><surname>Van Damme</surname><given-names>P</given-names></name><name><surname>Ruttens</surname><given-names>B</given-names></name><name><surname>Goethals</surname><given-names>M</given-names></name><name><surname>Demol</surname><given-names>H</given-names></name><name><surname>Timmerman</surname><given-names>E</given-names></name><name><surname>Vandekerckhove</surname><given-names>J</given-names></name><name><surname>Gevaert</surname><given-names>K</given-names></name></person-group>. <article-title>Selecting protein N-terminal peptides by combined fractional diagonal chromatography.</article-title><source>Nat Protoc</source>. <year>2011</year>;<volume>6</volume>:<fpage>1130</fpage>–<lpage>1141</lpage>. <comment>doi: 10.1038/nprot.2011.355</comment><pub-id pub-id-type="pmid">21799483</pub-id></mixed-citation>
              </ref>
              <ref id="R40">
                <label>40.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Damme</surname><given-names>P</given-names></name><name><surname>Van Damme</surname><given-names>J</given-names></name><name><surname>Demol</surname><given-names>H</given-names></name><name><surname>Staes</surname><given-names>A</given-names></name><name><surname>Vandekerckhove</surname><given-names>J</given-names></name><name><surname>Gevaert</surname><given-names>K</given-names></name></person-group>. <article-title>A review of COFRADIC techniques targeting protein N-terminal acetylation.</article-title><source>BMC Proc</source>. <year>2009</year>;<volume>3</volume><issue>suppl 6</issue><fpage>S6</fpage>. <comment>doi: 10.1186/1753-6561-3-S6-S6</comment></mixed-citation>
              </ref>
              <ref id="R41">
                <label>41.</label>
                <mixed-citation publication-type="journal"><collab>UniProt Consortium</collab>. <article-title>UniProt: a worldwide hub of protein knowledge.</article-title><source>Nucleic Acids Res</source>. <year>2019</year>;<volume>47</volume>:<fpage>D506</fpage>–<lpage>D515</lpage><pub-id pub-id-type="pmid">30395287</pub-id></mixed-citation>
              </ref>
              <ref id="R42">
                <label>42.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Walz</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Carattini-Rivera</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Vogel</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>N</given-names></name><name><surname>Justice</surname><given-names>MJ</given-names></name><name><surname>Bradley</surname><given-names>A</given-names></name><name><surname>Lupski</surname><given-names>JR</given-names></name></person-group>. <article-title>COP9 signalosome subunit 3 is essential for maintenance of cell proliferation in the mouse embryonic epiblast.</article-title><source>Mol Cell Biol</source>. <year>2003</year>;<volume>23</volume>:<fpage>6798</fpage>–<lpage>6808</lpage>. <comment>doi: 10.1128/mcb.23.19.6798-6808.2003</comment><pub-id pub-id-type="pmid">12972600</pub-id></mixed-citation>
              </ref>
              <ref id="R43">
                <label>43.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Cooke</surname><given-names>M</given-names></name><name><surname>Panjwani</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>K</given-names></name><name><surname>Krauth</surname><given-names>B</given-names></name><name><surname>Ho</surname><given-names>PY</given-names></name><name><surname>Medrzycki</surname><given-names>M</given-names></name><name><surname>Berhe</surname><given-names>DT</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>McDevitt</surname><given-names>TC</given-names></name><etal/></person-group>. <article-title>Histone h1 depletion impairs embryonic stem cell differentiation.</article-title><source>PLoS Genet</source>. <year>2012</year>;<volume>8</volume>:<fpage>e1002691</fpage>. <comment>doi: 10.1371/journal.pgen.1002691</comment><pub-id pub-id-type="pmid">22589736</pub-id></mixed-citation>
              </ref>
              <ref id="R44">
                <label>44.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangé</surname><given-names>A</given-names></name><name><surname>Coyaud</surname><given-names>E</given-names></name><name><surname>Desmetz</surname><given-names>C</given-names></name><name><surname>Laurent</surname><given-names>E</given-names></name><name><surname>Béganton</surname><given-names>B</given-names></name><name><surname>Coopman</surname><given-names>P</given-names></name><name><surname>Raught</surname><given-names>B</given-names></name><name><surname>Solassol</surname><given-names>J</given-names></name></person-group>. <article-title>FKBP4 connects mTORC2 and PI3K to activate the PDK1/Akt-dependent cell proliferation signaling in breast cancer.</article-title><source>Theranostics</source>. <year>2019</year>;<volume>9</volume>:<fpage>7003</fpage>–<lpage>7015</lpage>. <comment>doi: 10.7150/thno.35561</comment><pub-id pub-id-type="pmid">31660083</pub-id></mixed-citation>
              </ref>
              <ref id="R45">
                <label>45.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>T</given-names></name><name><surname>Mercer</surname><given-names>CA</given-names></name><name><surname>Hexley</surname><given-names>P</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Fumagalli</surname><given-names>S</given-names></name></person-group>. <article-title>Loss of tumor suppressor RPL5/RPL11 does not induce cell cycle arrest but impedes proliferation due to reduced ribosome content and translation capacity.</article-title><source>Mol Cell Biol</source>. <year>2013</year>;<volume>33</volume>:<fpage>4660</fpage>–<lpage>4671</lpage>. <comment>doi: 10.1128/MCB.01174-13</comment><pub-id pub-id-type="pmid">24061479</pub-id></mixed-citation>
              </ref>
              <ref id="R46">
                <label>46.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharjee</surname><given-names>RB</given-names></name><name><surname>Bag</surname><given-names>J</given-names></name></person-group>. <article-title>Depletion of nuclear poly(A) binding protein PABPN1 produces a compensatory response by cytoplasmic PABP4 and PABP5 in cultured human cells.</article-title><source>PLoS One</source>. <year>2012</year>;<volume>7</volume>:<fpage>e53036</fpage>. <comment>doi: 10.1371/journal.pone.0053036</comment><pub-id pub-id-type="pmid">23300856</pub-id></mixed-citation>
              </ref>
              <ref id="R47">
                <label>47.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhury</surname><given-names>KR</given-names></name><name><surname>Bucha</surname><given-names>S</given-names></name><name><surname>Baksi</surname><given-names>S</given-names></name><name><surname>Mukhopadhyay</surname><given-names>D</given-names></name><name><surname>Bhattacharyya</surname><given-names>NP</given-names></name></person-group>. <article-title>Chaperone-like protein HYPK and its interacting partners augment autophagy.</article-title><source>Eur J Cell Biol</source>. <year>2016</year>;<volume>95</volume>:<fpage>182</fpage>–<lpage>194</lpage>. <comment>doi: 10.1016/j.ejcb.2016.03.003</comment><pub-id pub-id-type="pmid">27067261</pub-id></mixed-citation>
              </ref>
              <ref id="R48">
                <label>48.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Mugler</surname><given-names>CF</given-names></name><name><surname>Keskin</surname><given-names>A</given-names></name><name><surname>Hodapp</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>LY</given-names></name><name><surname>Weis</surname><given-names>K</given-names></name><name><surname>Mertins</surname><given-names>P</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Jovanovic</surname><given-names>M</given-names></name><name><surname>Brar</surname><given-names>GA</given-names></name></person-group>. <article-title>Small and large ribosomal subunit deficiencies lead to distinct gene expression signatures that reflect cellular growth rate.</article-title><source>Mol Cell</source>. <year>2019</year>;<volume>73</volume>:<fpage>36</fpage>–<lpage>47.e10</lpage>. <comment>doi: 10.1016/j.molcel.2018.10.032</comment><pub-id pub-id-type="pmid">30503772</pub-id></mixed-citation>
              </ref>
              <ref id="R49">
                <label>49.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregory</surname><given-names>B</given-names></name><name><surname>Rahman</surname><given-names>N</given-names></name><name><surname>Bommakanti</surname><given-names>A</given-names></name><name><surname>Shamsuzzaman</surname><given-names>M</given-names></name><name><surname>Thapa</surname><given-names>M</given-names></name><name><surname>Lescure</surname><given-names>A</given-names></name><name><surname>Zengel</surname><given-names>JM</given-names></name><name><surname>Lindahl</surname><given-names>L</given-names></name></person-group>. <article-title>The small and large ribosomal subunits depend on each other for stability and accumulation.</article-title><source>Life Sci Alliance</source>. <year>2019</year>;<volume>2</volume>:<fpage>e201800150</fpage><pub-id pub-id-type="pmid">30837296</pub-id></mixed-citation>
              </ref>
              <ref id="R50">
                <label>50.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narla</surname><given-names>A</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name></person-group>. <article-title>Ribosomopathies: human disorders of ribosome dysfunction.</article-title><source>Blood</source>. <year>2010</year>;<volume>115</volume>:<fpage>3196</fpage>–<lpage>3205</lpage>. <comment>doi: 10.1182/blood-2009-10-178129</comment><pub-id pub-id-type="pmid">20194897</pub-id></mixed-citation>
              </ref>
              <ref id="R51">
                <label>51.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peisker</surname><given-names>K</given-names></name><name><surname>Braun</surname><given-names>D</given-names></name><name><surname>Wölfle</surname><given-names>T</given-names></name><name><surname>Hentschel</surname><given-names>J</given-names></name><name><surname>Fünfschilling</surname><given-names>U</given-names></name><name><surname>Fischer</surname><given-names>G</given-names></name><name><surname>Sickmann</surname><given-names>A</given-names></name><name><surname>Rospert</surname><given-names>S</given-names></name></person-group>. <article-title>Ribosome-associated complex binds to ribosomes in close proximity of Rpl31 at the exit of the polypeptide tunnel in yeast.</article-title><source>Mol Biol Cell</source>. <year>2008</year>;<volume>19</volume>:<fpage>5279</fpage>–<lpage>5288</lpage>. <comment>doi: 10.1091/mbc.e08-06-0661</comment><pub-id pub-id-type="pmid">18829863</pub-id></mixed-citation>
              </ref>
              <ref id="R52">
                <label>52.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steffen</surname><given-names>KK</given-names></name><name><surname>McCormick</surname><given-names>MA</given-names></name><name><surname>Pham</surname><given-names>KM</given-names></name><name><surname>MacKay</surname><given-names>VL</given-names></name><name><surname>Delaney</surname><given-names>JR</given-names></name><name><surname>Murakami</surname><given-names>CJ</given-names></name><name><surname>Kaeberlein</surname><given-names>M</given-names></name><name><surname>Kennedy</surname><given-names>BK</given-names></name></person-group>. <article-title>Ribosome deficiency protects against ER stress in Saccharomyces cerevisiae.</article-title><source>Genetics</source>. <year>2012</year>;<volume>191</volume>:<fpage>107</fpage>–<lpage>118</lpage>. <comment>doi: 10.1534/genetics.111.136549</comment><pub-id pub-id-type="pmid">22377630</pub-id></mixed-citation>
              </ref>
              <ref id="R53">
                <label>53.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khatter</surname><given-names>H</given-names></name><name><surname>Myasnikov</surname><given-names>AG</given-names></name><name><surname>Natchiar</surname><given-names>SK</given-names></name><name><surname>Klaholz</surname><given-names>BP</given-names></name></person-group>. <article-title>Structure of the human 80S ribosome.</article-title><source>Nature</source>. <year>2015</year>;<volume>520</volume>:<fpage>640</fpage>–<lpage>645</lpage>. <comment>doi: 10.1038/nature14427</comment><pub-id pub-id-type="pmid">25901680</pub-id></mixed-citation>
              </ref>
              <ref id="R54">
                <label>54.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphrey</surname><given-names>W</given-names></name><name><surname>Dalke</surname><given-names>A</given-names></name><name><surname>Schulten</surname><given-names>K</given-names></name></person-group>. <article-title>VMD: visual molecular dynamics.</article-title><source>J Mol Graph</source>. <year>1996</year>;<volume>14</volume>:<fpage>33</fpage>–<lpage>38, 27</lpage>. <comment>doi: 10.1016/0263-7855(96)00018-5</comment><pub-id pub-id-type="pmid">8744570</pub-id></mixed-citation>
              </ref>
              <ref id="R55">
                <label>55.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautschi</surname><given-names>M</given-names></name><name><surname>Just</surname><given-names>S</given-names></name><name><surname>Mun</surname><given-names>A</given-names></name><name><surname>Ross</surname><given-names>S</given-names></name><name><surname>Rücknagel</surname><given-names>P</given-names></name><name><surname>Dubaquié</surname><given-names>Y</given-names></name><name><surname>Ehrenhofer-Murray</surname><given-names>A</given-names></name><name><surname>Rospert</surname><given-names>S</given-names></name></person-group>. <article-title>The yeast N(alpha)-acetyltransferase NatA is quantitatively anchored to the ribosome and interacts with nascent polypeptides.</article-title><source>Mol Cell Biol</source>. <year>2003</year>;<volume>23</volume>:<fpage>7403</fpage>–<lpage>7414</lpage>. <comment>doi: 10.1128/mcb.23.20.7403-7414.2003</comment><pub-id pub-id-type="pmid">14517307</pub-id></mixed-citation>
              </ref>
              <ref id="R56">
                <label>56.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knorr</surname><given-names>AG</given-names></name><name><surname>Schmidt</surname><given-names>C</given-names></name><name><surname>Tesina</surname><given-names>P</given-names></name><name><surname>Berninghausen</surname><given-names>O</given-names></name><name><surname>Becker</surname><given-names>T</given-names></name><name><surname>Beatrix</surname><given-names>B</given-names></name><name><surname>Beckmann</surname><given-names>R</given-names></name></person-group>. <article-title>Ribosome-NatA architecture reveals that rRNA expansion segments coordinate N-terminal acetylation.</article-title><source>Nat Struct Mol Biol</source>. <year>2019</year>;<volume>26</volume>:<fpage>35</fpage>–<lpage>39</lpage>. <comment>doi: 10.1038/s41594-018-0165-y</comment><pub-id pub-id-type="pmid">30559462</pub-id></mixed-citation>
              </ref>
              <ref id="R57">
                <label>57.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polevoda</surname><given-names>B</given-names></name><name><surname>Brown</surname><given-names>S</given-names></name><name><surname>Cardillo</surname><given-names>TS</given-names></name><name><surname>Rigby</surname><given-names>S</given-names></name><name><surname>Sherman</surname><given-names>F</given-names></name></person-group>. <article-title>Yeast N(alpha)-terminal acetyltransferases are associated with ribosomes.</article-title><source>J Cell Biochem</source>. <year>2008</year>;<volume>103</volume>:<fpage>492</fpage>–<lpage>508</lpage>. <comment>doi: 10.1002/jcb.21418</comment><pub-id pub-id-type="pmid">17541948</pub-id></mixed-citation>
              </ref>
              <ref id="R58">
                <label>58.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varland</surname><given-names>S</given-names></name><name><surname>Arnesen</surname><given-names>T</given-names></name></person-group>. <article-title>Investigating the functionality of a ribosome-binding mutant of NAA15 using Saccharomyces cerevisiae.</article-title><source>BMC Res Notes</source>. <year>2018</year>;<volume>11</volume>:<fpage>404</fpage>. <comment>doi: 10.1186/s13104-018-3513-4</comment><pub-id pub-id-type="pmid">29929531</pub-id></mixed-citation>
              </ref>
              <ref id="R59">
                <label>59.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>G</given-names></name><name><surname>Boehringer</surname><given-names>D</given-names></name><name><surname>Ban</surname><given-names>N</given-names></name><name><surname>Bukau</surname><given-names>B</given-names></name></person-group>. <article-title>The ribosome as a platform for co-translational processing, folding and targeting of newly synthesized proteins.</article-title><source>Nat Struct Mol Biol</source>. <year>2009</year>;<volume>16</volume>:<fpage>589</fpage>–<lpage>597</lpage>. <comment>doi: 10.1038/nsmb.1614</comment><pub-id pub-id-type="pmid">19491936</pub-id></mixed-citation>
              </ref>
              <ref id="R60">
                <label>60.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>G</given-names></name><name><surname>Rauch</surname><given-names>T</given-names></name><name><surname>Rist</surname><given-names>W</given-names></name><name><surname>Vorderwülbecke</surname><given-names>S</given-names></name><name><surname>Patzelt</surname><given-names>H</given-names></name><name><surname>Schulze-Specking</surname><given-names>A</given-names></name><name><surname>Ban</surname><given-names>N</given-names></name><name><surname>Deuerling</surname><given-names>E</given-names></name><name><surname>Bukau</surname><given-names>B</given-names></name></person-group>. <article-title>L23 protein functions as a chaperone docking site on the ribosome.</article-title><source>Nature</source>. <year>2002</year>;<volume>419</volume>:<fpage>171</fpage>–<lpage>174</lpage>. <comment>doi: 10.1038/nature01047</comment><pub-id pub-id-type="pmid">12226666</pub-id></mixed-citation>
              </ref>
              <ref id="R61">
                <label>61.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>DN</given-names></name><name><surname>Nierhaus</surname><given-names>KH</given-names></name></person-group>. <article-title>Ribosomal proteins in the spotlight.</article-title><source>Crit Rev Biochem Mol Biol</source>. <year>2005</year>;<volume>40</volume>:<fpage>243</fpage>–<lpage>267</lpage>. <comment>doi: 10.1080/10409230500256523</comment><pub-id pub-id-type="pmid">16257826</pub-id></mixed-citation>
              </ref>
              <ref id="R62">
                <label>62.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Yong</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Single-cell transcriptome analysis maps the developmental track of the human heart.</article-title><source>Cell Rep</source>. <year>2019</year>;<volume>26</volume>:<fpage>1934</fpage>–<lpage>1950.e5</lpage>. <comment>doi: 10.1016/j.celrep.2019.01.079</comment><pub-id pub-id-type="pmid">30759401</pub-id></mixed-citation>
              </ref>
              <ref id="R63">
                <label>63.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnesen</surname><given-names>T</given-names></name><name><surname>Gromyko</surname><given-names>D</given-names></name><name><surname>Kagabo</surname><given-names>D</given-names></name><name><surname>Betts</surname><given-names>MJ</given-names></name><name><surname>Starheim</surname><given-names>KK</given-names></name><name><surname>Varhaug</surname><given-names>JE</given-names></name><name><surname>Anderson</surname><given-names>D</given-names></name><name><surname>Lillehaug</surname><given-names>JR</given-names></name></person-group>. <article-title>A novel human NatA Nalpha-terminal acetyltransferase complex: hNaa16p-hNaa10p (hNat2-hArd1).</article-title><source>BMC Biochem</source>. <year>2009</year>;<volume>10</volume>:<fpage>15</fpage>. <comment>doi: 10.1186/1471-2091-10-15</comment><pub-id pub-id-type="pmid">19480662</pub-id></mixed-citation>
              </ref>
              <ref id="R64">
                <label>64.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magin</surname><given-names>RS</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Cooperman</surname><given-names>B</given-names></name><name><surname>Marmorstein</surname><given-names>R</given-names></name></person-group>. <article-title>Probing the interaction between NatA and the ribosome for co-translational protein acetylation.</article-title><source>PLoS One</source>. <year>2017</year>;<volume>12</volume>:<fpage>e0186278</fpage>. <comment>doi: 10.1371/journal.pone.0186278</comment><pub-id pub-id-type="pmid">29016658</pub-id></mixed-citation>
              </ref>
              <ref id="R65">
                <label>65.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>AJ</given-names></name></person-group>. <article-title>Molecular basis of the human ribosomopathy Shwachman-Diamond syndrome.</article-title><source>Adv Biol Regul</source>. <year>2018</year>;<volume>67</volume>:<fpage>109</fpage>–<lpage>127</lpage>. <comment>doi: 10.1016/j.jbior.2017.09.002</comment><pub-id pub-id-type="pmid">28942353</pub-id></mixed-citation>
              </ref>
              <ref id="R66">
                <label>66.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrar</surname><given-names>JE</given-names></name><name><surname>Nater</surname><given-names>M</given-names></name><name><surname>Caywood</surname><given-names>E</given-names></name><name><surname>McDevitt</surname><given-names>MA</given-names></name><name><surname>Kowalski</surname><given-names>J</given-names></name><name><surname>Takemoto</surname><given-names>CM</given-names></name><name><surname>Talbot</surname><given-names>CC</given-names><suffix>Jr</suffix></name><name><surname>Meltzer</surname><given-names>P</given-names></name><name><surname>Esposito</surname><given-names>D</given-names></name><name><surname>Beggs</surname><given-names>AH</given-names></name><etal/></person-group>. <article-title>Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia.</article-title><source>Blood</source>. <year>2008</year>;<volume>112</volume>:<fpage>1582</fpage>–<lpage>1592</lpage>. <comment>doi: 10.1182/blood-2008-02-140012</comment><pub-id pub-id-type="pmid">18535205</pub-id></mixed-citation>
              </ref>
              <ref id="R67">
                <label>67.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gazda</surname><given-names>HT</given-names></name><name><surname>Sheen</surname><given-names>MR</given-names></name><name><surname>Vlachos</surname><given-names>A</given-names></name><name><surname>Choesmel</surname><given-names>V</given-names></name><name><surname>O’Donohue</surname><given-names>MF</given-names></name><name><surname>Schneider</surname><given-names>H</given-names></name><name><surname>Darras</surname><given-names>N</given-names></name><name><surname>Hasman</surname><given-names>C</given-names></name><name><surname>Sieff</surname><given-names>CA</given-names></name><name><surname>Newburger</surname><given-names>PE</given-names></name><etal/></person-group>. <article-title>Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients.</article-title><source>Am J Hum Genet</source>. <year>2008</year>;<volume>83</volume>:<fpage>769</fpage>–<lpage>780</lpage>. <comment>doi: 10.1016/j.ajhg.2008.11.004</comment><pub-id pub-id-type="pmid">19061985</pub-id></mixed-citation>
              </ref>
              <ref id="R68">
                <label>68.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vlachos</surname><given-names>A</given-names></name><name><surname>Osorio</surname><given-names>DS</given-names></name><name><surname>Atsidaftos</surname><given-names>E</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Lababidi</surname><given-names>ML</given-names></name><name><surname>Seiden</surname><given-names>HS</given-names></name><name><surname>Gruber</surname><given-names>D</given-names></name><name><surname>Glader</surname><given-names>BE</given-names></name><name><surname>Onel</surname><given-names>K</given-names></name><name><surname>Farrar</surname><given-names>JE</given-names></name><etal/></person-group>. <article-title>Increased prevalence of congenital heart disease in children with Diamond Blackfan anemia suggests unrecognized Diamond Blackfan anemia as a cause of congenital heart disease in the general population: a report of the Diamond Blackfan Anemia Registry.</article-title><source>Circ Genom Precis Med</source>. <year>2018</year>;<volume>11</volume>:<fpage>e002044</fpage>. <comment>doi: 10.1161/CIRCGENETICS.117.002044</comment><pub-id pub-id-type="pmid">29748317</pub-id></mixed-citation>
              </ref>
              <ref id="R69">
                <label>69.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machet</surname><given-names>L</given-names></name></person-group>. <article-title>[Genetic diseases on the Internet: OMIM].</article-title><source>Ann Dermatol Venereol</source>. <year>1998</year>;<volume>125</volume>:<fpage>645</fpage><pub-id pub-id-type="pmid">9805561</pub-id></mixed-citation>
              </ref>
              <ref id="R70">
                <label>70.</label>
                <mixed-citation publication-type="web"><collab>Online Mendelian Inheritance in Man, OMIM®</collab>. <article-title>McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore.</article-title><comment>Accessed April 2020. <ext-link ext-link-type="uri" xlink:href="https://omim.org/">https://omim.org/</ext-link></comment></mixed-citation>
              </ref>
              <ref id="R71">
                <label>71.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyston</surname><given-names>J</given-names></name></person-group>. <article-title>Online Mendelian Inheritance in Man.</article-title><source>Anesthesiology</source>. <year>1998</year>;<volume>89</volume>:<fpage>811</fpage>–<lpage>812</lpage>. <comment>doi: 10.1097/00000542-199809000-00060</comment><pub-id pub-id-type="pmid">9743436</pub-id></mixed-citation>
              </ref>
              <ref id="R72">
                <label>72.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auton</surname><given-names>A</given-names></name><name><surname>Brooks</surname><given-names>LD</given-names></name><name><surname>Durbin</surname><given-names>RM</given-names></name><name><surname>Garrison</surname><given-names>EP</given-names></name><name><surname>Kang</surname><given-names>HM</given-names></name><name><surname>Korbel</surname><given-names>JO</given-names></name><name><surname>Marchini</surname><given-names>JL</given-names></name><name><surname>McCarthy</surname><given-names>S</given-names></name><name><surname>McVean</surname><given-names>GA</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name></person-group>; <collab>1000 Genomes Project Consortium</collab>. <article-title>A global reference for human genetic variation.</article-title><source>Nature</source>. <year>2015</year>;<volume>526</volume>:<fpage>68</fpage>–<lpage>74</lpage>. <comment>doi: 10.1038/nature15393</comment><pub-id pub-id-type="pmid">26432245</pub-id></mixed-citation>
              </ref>
              <ref id="R73">
                <label>73.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname><given-names>A</given-names></name><name><surname>Hanna</surname><given-names>M</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>Sivachenko</surname><given-names>A</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Kernytsky</surname><given-names>A</given-names></name><name><surname>Garimella</surname><given-names>K</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Daly</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.</article-title><source>Genome Res</source>. <year>2010</year>;<volume>20</volume>:<fpage>1297</fpage>–<lpage>1303</lpage>. <comment>doi: 10.1101/gr.107524.110</comment><pub-id pub-id-type="pmid">20644199</pub-id></mixed-citation>
              </ref>
              <ref id="R74">
                <label>74.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Auwera</surname><given-names>GA</given-names></name><name><surname>Carneiro</surname><given-names>MO</given-names></name><name><surname>Hartl</surname><given-names>C</given-names></name><name><surname>Poplin</surname><given-names>R</given-names></name><name><surname>Del Angel</surname><given-names>G</given-names></name><name><surname>Levy-Moonshine</surname><given-names>A</given-names></name><name><surname>Jordan</surname><given-names>T</given-names></name><name><surname>Shakir</surname><given-names>K</given-names></name><name><surname>Roazen</surname><given-names>D</given-names></name><name><surname>Thibault</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline.</article-title><source>Curr Protoc Bioinformatics</source>. <year>2013</year>;<volume>43</volume>:<fpage>11.10.1</fpage>–<lpage>11.10.33</lpage>. <comment>doi: 10.1002/0471250953.bi1110s43</comment><pub-id pub-id-type="pmid">25431634</pub-id></mixed-citation>
              </ref>
              <ref id="R75">
                <label>75.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>C</given-names></name><name><surname>Wei</surname><given-names>P</given-names></name><name><surname>Jian</surname><given-names>X</given-names></name><name><surname>Gibbs</surname><given-names>R</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name></person-group>. <article-title>Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies.</article-title><source>Hum Mol Genet</source>. <year>2015</year>;<volume>24</volume>:<fpage>2125</fpage>–<lpage>2137</lpage>. <comment>doi: 10.1093/hmg/ddu733</comment><pub-id pub-id-type="pmid">25552646</pub-id></mixed-citation>
              </ref>
              <ref id="R76">
                <label>76.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>J</given-names></name><name><surname>Hein</surname><given-names>MY</given-names></name><name><surname>Luber</surname><given-names>CA</given-names></name><name><surname>Paron</surname><given-names>I</given-names></name><name><surname>Nagaraj</surname><given-names>N</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name></person-group>. <article-title>Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ.</article-title><source>Mol Cell Proteomics</source>. <year>2014</year>;<volume>13</volume>:<fpage>2513</fpage>–<lpage>2526</lpage>. <comment>doi: 10.1074/mcp.M113.031591</comment><pub-id pub-id-type="pmid">24942700</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <sec>
              <title>Novelty and Significance</title>
              <sec>
                <title>What Is Known?</title>
                <list list-type="bullet">
                  <list-item>
                    <p>NAA15 (N-alpha-acetyltransferase 15) is an 866 amino acid subunit of the NatA (N-terminal acetyltransferase), which acetylates the N-terminal residue of many eukaryotic proteins.</p>
                  </list-item>
                  <list-item>
                    <p>Patients with congenital heart disease (CHD) have genetic variants in the NAA15 gene predicted to be harmful, yet there is limited knowledge of how NAA15 variants cause CHD.</p>
                  </list-item>
                  <list-item>
                    <p>Human induced pluripotent stem cells (iPSCs) can be used as a human model to study biological consequences of genetic variants that may cause disease.</p>
                  </list-item>
                </list>
              </sec>
              <sec>
                <title>What New Information Does This Article Contribute?</title>
                <list list-type="bullet">
                  <list-item>
                    <p>Exome sequence analysis of 4511 patients with CHD identified 20 subjects with rare inherited or de novo variants predicted to perturb NAA15, which may be responsible for their condition.</p>
                  </list-item>
                  <list-item>
                    <p>NAA15 haploinsufficiency in iPSCs has little effect on the transcriptome. However, a 50% reduction of NAA15 protein does lead to impaired cardiomyocyte contractility and proteome integrity.</p>
                  </list-item>
                  <list-item>
                    <p>Expression levels of ribosome-associated proteins and 4 proteins that encode genes known to cause autosomal dominant CHD are altered in NAA15 haploinsufficient and deficient iPSCs.</p>
                  </list-item>
                </list>
                <p>CHD, which affects about 1% of newborns, reflects defects in heart development during fetal life. Defining genetic causes of CHD provides new insights into mechanisms of cardiac development that may eventually benefit patients with CHD and their families. We have used induced pluripotent stem cells to model NAA15 haploinsufficiency. In iPSCs, NAA15 haploinsufficiency and deficiency cause loss of N-terminal acetylation of 9 and 32 proteins. In addition, we discovered 562 proteins with altered expression levels; 18 proteins are ribosome-associated. Among affected proteins, 4 proteins are known CHD genes and are likely candidates that require a full complement of NAA15. We conclude that patients with CHD with NAA15 haploinsufficiency likely have altered ribosomal activity, which effects steady-state levels of proteins essential for early cardiac development. Genetically engineered iPSCs can be used as a platform for defining the potential pathogenicity of NAA15 variants of unknown significance.</p>
              </sec>
            </sec>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
